Avant Diagnostics 10-K 28 Aug 18 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2016	Aug. 07, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Avant Diagnostics, Inc
Entity Central Index Key	1,451,929
Trading Symbol	AVDX
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Document Type	10-K
Document Period End Date	Sep. 30, 2016
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float	$ 55,317,921
Entity Common Stock, Shares Outstanding		336,957,722

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Current Assets:
Cash	$ 851	$ 43,635
Accounts receivable	41,383
Prepaid expenses		42
Total current assets	42,234	43,677
Non-current Assets
Intellectual Property	5,497,134	1,651,875
Website development cost, net	5,312
Patent costs, net	111,361	143,178
Other Assets	20,000
Total non-current assets	5,633,807	1,795,053
Total Assets	5,676,041	1,838,730
Current Liabilities:
Accounts payable	536,630	159,598
Accrued payroll and benefits	518,932	320,000
Due to related party	256,480	141,717
Convertible notes payable	250,807
Convertible notes payable, net of unamortized discount of $70,720	429,280
Derivative liability	123,239
Total current liabilities	2,115,369	621,315
Total Liabilities	2,115,369	621,315
Commitments and Contingencies
Stockholders' Equity
Common Stock, $0.00001 par value, 450,000,000 shares authorized; 219,254,543 and 95,944,743 shares outstanding as of September 30, 2016 and September 30, 2015, respectively	2,193	959
Additional paid-in capital	25,131,601	11,030,534
Accumulated deficit	(21,573,123)	(9,814,078)
Total Stockholders' Equity	3,560,671	1,217,415
Total Liabilities and Stockholders' Equity	5,676,041	1,838,730
Series B preferred stock
Stockholders' Equity
Preferred stock, $0.001 par value; 50,000,000 shares authorized

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Net of unamortized discount	$ 70,720
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares outstanding	219,254,543	95,944,743
Series B preferred stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000	3,000
Preferred stock, shares issued
Preferred stock, shares outstanding

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Revenue	$ 118,040
Cost of revenue	52,522
Gross profit	65,518
Operating expenses:
Selling, general and administrative	1,230,992	566,416
Research and development		25,000
Research and development - license acquired	10,080,000
Professional fees	313,275	110,536
Merger costs		641,126
Total operating expenses	11,624,267	1,343,078
Loss from operations	(11,558,749)	(1,343,078)
Other expense
Impairment of available for sale securities		2,000,000
Interest expense	(114,253)
Loss on change in fair value of derivative	(126,344)
Gain on extinguishment of debt	40,302
Total other expense	(200,295)	2,000,000
Net Loss	$ (11,759,045)	$ (3,343,078)
Loss per Share:
Basic and diluted net loss per common share outstanding	$ (0.08)	$ (0.04)
Basic and diluted weighted average number of common shares outstanding	146,223,688	85,838,985
Comprehensive loss:
Net loss	$ (11,759,045)	$ (3,343,078)
Adjustment for realized loss on available for sale securities		400,000
Comprehensive loss	$ (11,759,045)	$ (2,943,078)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Total	Preferred stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance at Sep. 30, 2014	$ 3,133,000		$ 717	$ 10,003,283	$ (400,000)	$ (6,471,000)
Beginning balance, shares at Sep. 30, 2014			71,656,000
Effect of reverse merger: Shares yet to be surrendered in recapitalization			$ (36)	36
Effect of reverse merger: Shares yet to be surrendered in recapitalization, shares			(3,557,777)
Common stock issued in connection with shares exchange transaction	(70,003)		$ 65	(70,068)
Common stock issued in connection with shares exchange transaction, shares			6,467,000
Fair value of warrants in connection with recapitalization	641,126			641,126
Sale of common stock	340,000		$ 28	339,972
Sale of common stock, shares			2,781,668
Common stock issued for services	115,070		$ 16	115,054
Common stock issued for services, shares			1,715,500
Common stock issued in exchange with exercise of warrants	700		$ 70	630
Common stock issued in exchange with exercise of warrants, shares			7,000,000
Common stock issued in exchange with exercise of options	600		$ 60	540
Common stock issued in exchange with exercise of options, shares			6,000,000
Common stock issued in exchange with exercise of options on a cashless basis			$ 39	(39)
Common stock issued in exchange with exercise of options on a cashless basis, shares			3,882,352
Reclassification of unrealized loss upon impairment of available for sale security	400,000				400,000
Net loss	(3,343,078)					(3,343,078)
Ending balance at Sep. 30, 2015	1,217,415		$ 959	11,030,534		(9,814,078)
Ending balance, shares at Sep. 30, 2015			95,944,743
Sale of common stock	310,000		$ 62	309,938
Sale of common stock, shares			6,200,000
Common stock issued for services	25,022		$ 32	24,990
Common stock issued for services, shares			3,190,000
Common stock issued to acquire net assets of THI	3,150,000		$ 250	3,149,750
Common stock issued to acquire net assets of THI, shares			25,000,000
Common stock issued to acquire net assets of ADI	10,080,000		$ 800	10,079,200
Common stock issued to acquire net assets of ADI, shares			80,000,000
Stock based compensation	52,500			52,500
Common stock issued to pay debt to officer	428,575		$ 86	428,489
Common stock issued to pay debt to officer, shares			8,569,800
Adjustment related to prior period			$ 4	(4)
Adjustment related to prior period, shares			350,000
Reclass derivative liability to equity upon note payments	52,389			52,389
Reclass derivative liability to equity upon note payments, shares
THI invoices paid off before THI was purchased	3,815			3,815
Net loss	(11,759,045)					(11,759,045)
Ending balance at Sep. 30, 2016	$ 3,560,671		$ 2,193	$ 25,131,601		$ (21,573,123)
Ending balance, shares at Sep. 30, 2016			219,254,543

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash Flows from Operating Activities:
Net loss	$ (11,759,045)	$ (3,343,078)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	340,039
Amortization of debt discounts	18,865
Merger costs		641,126
Impairment on available for sale securities		2,000,000
Research and development - license acquired	10,080,000
Stock-based compensation expenses	77,522	115,068
Loss on change in fair value of derivatives	86,042
Changes in operating assets and liabilities:
Accounts receivable	64,251
Prepaid expenses	42	(42)
Accounts payable	174,390	(24,403)
Accrued payroll and benefits		320,000
Accrued liabilities	234,890	89,717
Net cash used in operating activities	(683,004)	(201,612)
Cash Flows from Investing Activities:
Cash acquired with acquisition of Theranostics Health, Inc. assets	37,519
Licensing costs	(16,856)	(102,053)
Shares in Arrayit	(20,000)
Website development costs	(21,250)
Net cash provided by (used in) investing activities	(20,587)	(102,053)
Cash Flows from Financing Activities:
Proceeds from sale of common stock, net	310,000	340,000
Proceeds from warrant and option exercises		1,300
Proceeds from convertible notes payable	250,807
Proceeds from convertible notes payable, related party	100,000
Net cash provided by financing activities	660,807	341,300
Net increase in cash	(42,784)	37,635
Cash at beginning of period	43,635	6,000
Cash at end of period	851	43,635
Supplemental disclosure of noncash investing and financing activities:
Net liabilities assumed in connection with recapitalization		70,003
Effect of recapitalization		71,384
Shares issued in settlement of related party debt	428,575
Reclass derivative liability to equity upon note payment	52,389
Common stock issued to acquire net assets of Theranostics Health, Inc.	3,150,000
Common stock issued to acquire net assets of Amarantus Diagnostics, Inc.	$ 10,080,000

Nature of Operations and Basis

Nature of Operations and Basis of Presentation	12 Months Ended
	Sep. 30, 2016
Nature of Operations and Basis of Presentation [Abstract]
NATURE OF OPERATIONS AND BASIS OF PRESENTATION	NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION Avant Diagnostics, Inc. (“Avant”, “we” or the “Company”), a Nevada corporation established in 2009, is a commercial-stage molecular diagnostic company that focuses on the development and commercialization of a series of proprietary diagnostic tests that provide important actionable information for physicians and patients in the areas of cancers. Avant was originally named Arrayit Diagnostics, Inc. which was formed as a majority owned subsidiary of Arrayit Corporation (“Arrayit”) through a technology transfer in July 2009. In January 2013, the Company effected a name change to Avant Diagnostics, Inc. In May of 2016, the Company acquired assets from Theranostics Health, Inc. and Amarantus Diagnostics, Inc. to significantly expand its pipeline and position itself for commercialization. Basis of Presentation Effective December 29, 2014, we completed a reverse recapitalization, as agreed in the definitive Agreement and Plan of Reorganization, of 100% of the outstanding equity interests of American Liberty Petroleum Corp. (“ALP”). Avant shareholders received approximately 74,500,000 shares of common stock for a 93% equity interest in ALP. Such share exchange was calculated based on a one-for-one conversion ratio after a 1 for 17 reverse stock split of ALP which was subsequently effected in March 2015. The split affected the ALP common stock and not the Avant common stock. All references in these consolidated financial statements to the number of shares, options and other common stock equivalents, price per share and weighted-average number of shares outstanding of common stock have been adjusted to retroactively reflect the effect of the stock split. Per the terms of the Agreement and Plan of Reorganization, ALP was delivered with zero assets and $70,000 in liabilities at time of closing. Following the reverse merger, we changed the name of ALP to “Avant Diagnostics, Inc.” The transaction was regarded as a reverse recapitalization whereby Avant was considered to be the accounting acquirer as it retained control of ALP after the exchange. Although ALP is the legal parent company, the share exchange was treated as a recapitalization of ALP. Avant is the continuing entity for financial reporting purposes. Accordingly, the assets and liabilities and the historical operations reflected in the financial statements are those of Avant for all periods presented. In conjunction with the reverse recapitalization, Issuers Capital Advisors, LLC, an entity controlled by the Company’s former President and CEO, was granted 5,000,000 warrants with a fair value of $641,126. The cost of the warrants are recognized on the Consolidated Statement of Operations as Merger costs. As of September 30, 2015 , there remained a total 3,557,777 shares of common stock that still had not been converted by Avant shareholders as part of the reverse recapitalization. The Agreement and Plan of Reorganization does not provide for cash in lieu of exchange of shares and provides that upon the merger, the shareholders acquired their rights in ALP shares and all outstanding shares of Avant were deemed to be cancelled. There is no timeframe as to when the shareholders must convert their shares and, as of the date of this report, the shares have not been issued. On January 27, 2015, the Company effected a change in the par value of its common stock to $0.00001 per share. Accordingly, the Company has recorded a retroactive reclassification to reflect the change in par value on its consolidated balance sheets for all periods presented. On May 11, 2016, the Company acquired substantially all of the assets and assumed certain liabilities related to the business of Theranostics Health, Inc., a Delaware corporation (“ THI On May 11, 2016, the Company acquired Amarantus Diagnostics, Inc., a Delaware corporation (“ADI”), from Amarantus Bioscience Holdings, Inc. (the “Shareholder”). ADI owns an exclusive worldwide sub-license to the Lymphocyte Proliferation test (LymPro Test™) for Alzheimer’s disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig. In addition, ADI holds an exclusive worldwide license to MSPrecise Ò The Company also owns an exclusive license and has distribution rights for OvaDx®, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. Prior to the acquisitions of assets from THI and ADI, the Company’s primary activities since inception had been focused on preparing sample specimens in order for OvaDx® to be further tested according to the guidelines outlined by the Food & Drug Administration for the commercial development of diagnostic tests. The Company intends to continue to conduct research & development activities to prepare OvaDx® for the market.

Going Concern and Management's

Going Concern and Management's Liquidity Plans	12 Months Ended
	Sep. 30, 2016
Going Concern And Management's Liquidity Plans [Abstract]
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS Since inception, the Company has financed its operations primarily through equity and debt financings and advances from related parties. As of September 30, 2016 and 2015, the Company had an accumulated deficit of $21.6 million and $9.8 million, respectively. During the year ended September 30, 2016 and 2015, the Company incurred net losses of $11.8 million and $3.4 million, respectively, and used cash in operating activities of $683,000 and $202,000, respectively. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company recognizes it will need to raise additional capital in order to fund operations, meet its payment obligations and execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will generate revenues, become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds on favorable terms, it will have to develop and implement a plan to further extend payables and to raise capital through the issuance of debt or equity on less favorable terms until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. If the Company is unable to obtain financing on a timely basis, the Company could be forced to sell its assets, discontinue its operations and/or pursue other strategic avenues to commercialize its technology, and its intellectual property could be impaired.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Sep. 30, 2016
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Theranostics Health, Inc. and Amarantus Diagnostics Inc. All intercompany transactions and balances have been eliminated in consolidation. Acquisitions Amarantus Diagnostics, Inc. On May 11, 2016, the Company entered into a Share Exchange Agreement (the “Exchange Agreement”) with Shareholder to purchase 100% of the outstanding capital stock of ADI (the “ADI Acquisition”). The Company paid an aggregate consideration of 80,000,000 shares of its common stock and a $50,000 convertible promissory note for the ADI Acquisition, subject to the issuance of additional shares upon the occurrence of certain events set forth in the Share Exchange Agreement. Each share of Avant common stock issued in connection with the ADI Acquisition shall be subject to a lock-up beginning on the May 11, 2016 and ending on the earlier of (i) eighteen (18) months after such date or (ii) a Change in Control (as defined in the Exchange Agreement) or (iii) written consent of the parties that certain escrow agreement entered into between the Company, ADI, the Shareholder and certain creditors of the Shareholder. The convertible promissory note issued bears interest at 12% per annum and matures one year from the date of issuance. The note will be convertible at the option of the Investor at any time into shares of common stock, at an initial conversion price equal to $0.20, subject to adjustment. On May 12, 2016, as part of the agreement with ADI, the Company has the right to offset the $100,000 promissory note due to Shareholder, for the assumption of certain liabilities and expenses in connection with the transaction. A summary of consideration is as follows: 80,000,000 shares of the Company’s common stock $ 10,080,000 Total purchase price 10,080,000 The transaction was accounted for as an asset acquisition pursuant to ASU 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business, as the majority of the fair value of the assets acquired was concentrated in a group of similar assets, and the acquired assets did not have outputs or employees. The assets acquired under the Exchange Agreement include exclusive worldwide sub-license to the Lymphocyte Proliferation test (LymPro Test™) for Alzheimer’s disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig. In addition, ADI holds an exclusive worldwide license to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation. Additionally, ADI owns intellectual property for the diagnosis of Parkinson’s disease (NuroPro) and Breast Cancer (BC SeraPro). The $10.1 million purchase price paid to date for these assets has been expensed in the Company’s statement of operations for the period ended September 30, 2016. Theranostics Health, Inc. On May 11, 2016, the Company entered into an Asset Purchase Agreement (“THI Purchase Agreement”) with Theranostics Health, Inc. (“THI”). The Company purchased substantially all of the assets related to THI’s business and assumed certain liabilities (the “THI Acquisition”). The Company paid an aggregate consideration of 25,000,000 shares of its common stock for the THI Acquisition. Each share of Avant common stock issued in connection with the THI Acquisition shall be subject to a lock-up beginning on May 11, 2016 and ending on the earlier of (i) eighteen (18) months after such date or (ii) a Change in Control (as defined in the Exchange Agreement) or (iii) written consent of the Company, at the Company’s sole discretion. A summary of consideration is as follows: 25,000,000 shares of the Company’s common stock $ 3,150,000 The following summarizes the current estimates of fair value of assets acquired and liabilities assumed: Amount Assets acquired: Cash $ 37,519 Accounts receivable 105,634 Intellectual property 4,120,687 Liabilities assumed: Accounts payable and accrued expenses (705,498 ) Derivative liability (8,342 ) Note payable, related party (400,000 ) Net assets acquired $ 3,150,000 The assets of the acquired consist primarily of intellectual property intangible assets. An analysis by the Company determined that substantially all the fair value of the assets on the date of acquisition is captured in the intellectual property intangible assets, as the cash and accounts receivable account for a relatively immaterial portion of the fair market value of the total assets received. The THI Acquisition was accounted for as an asset purchase in accordance with ASU 2017-01. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company’s significant estimates include the valuation of derivative liabilities, useful lives of long-lived assets, the valuation of debt and equity instruments, the valuation allowance relating to stock based compensation and the Company’s deferred tax assets. Actual results could differ from those estimates. Revenue Recognition For revenue from product sales and services, the Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product or services has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required. The Company derives its revenue from the performance under research and development contracts. These contracts require the Company to provide services directed towards specific objectives and include developmental milestones and deliverables. Up-front payments are recorded as deferred revenue and recognized when milestones are achieved. The Company may be reimbursed for certain costs incurred in preforming the specific research and development activities and records the reimbursement as revenues. As of September 30, 2016, and 2015, deferred revenue was $-0- and $-0-. Cost of Sales and Service The cost of sales and service consists of the cost of labor, equipment depreciation, and supplies and materials. Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of September 30, 2016, and 2015, allowance for doubtful accounts was $-0-. Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight line method over their estimated useful lives as follows: Office equipment 5 years Lab equipment 3 to 7 years Net Loss per Share of Common Stock The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period, adjusted to give effect to the 17-for-1 reverse stock split, which was effective in the market in March 2015 (see Note 1), and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share for the years ended September 30, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: September 30, September 30, 2016 2015 Shares issued upon conversion of convertible notes and accrued interest $ 1,776,549 $ - Intangible Assets The Company’s intangible assets consists of the following: Intellectual property for the technology transfer agreement and licensing payments for use of various patent for its worldwide exclusive licensed rights to OvaDx®, a diagnostic screening test for the early detection of ovarian cancer. As of September 30, 2016, the Company has not yet received FDA approval with respect to the clinical use of these intangible assets. The carrying value of September 30, 2016 and 2015 was $1,483,000 and $1,652,000 respectively. Intellectual property acquired from the THI Acquisition leading to the development of proteomic technologies for measuring the activation status of key signaling pathways that are instrumental in the development of companion diagnostics for molecular-targeted therapies. The Company uses these proteomic technologies to support the drug development programs of most major pharmaceutical and biotechnology drug development companies. The carrying value of September 30, 2016 and 2015 was $4,014,000 and -0-, respectively. Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Company’s intangible asset with a finite life included intellectual property acquired from THI Acquisition, capitalized website development costs and patent costs, which are being amortized over their economic or legal life, whichever is shorter. The gross carrying amounts and accumulated amortization related to acquired intangible assets as of September 30, 2016 are as follows (in thousands, except year amounts): Description Book Value as of Remaining Life (in years) Additions during Amortization Expense for the Year Ended September 30, 2016 Book Value as of License Rights to OvaDx $ 1,652 9 $ 17 $ 185 $ 1,484 THI Acquisition on May 11, 2016 - 15 $ 4,121 107 4,014 Website development cost - 5 21 16 5 Patent costs 143 9 32 111 $ 1,795 $ 4,159 $ 340 $ 5,614 The Company incurred amortization expense associated with its finite-lived intangible assets of approximately $340,000 for the year ended September 30, 2016. Impairment of Long-Lived Assets T he Company reviews the carrying value of intangibles and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair market value. During the year ended September 30, 2016 and 2015, the Company management performed an evaluation of its acquired intangible assets as of September 30, 2016 and 2015 and no impairment was deemed to exist as of September 30, 2016 and 2015. Considerable management judgment is necessary to estimate the fair value. Accordingly, actual results could vary significantly from management's estimates. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the condensed consolidated statements of operations and comprehensive loss, as if such amounts were paid in cash. Convertible Instruments U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable ASC 480-10. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. Derivative Financial Instruments The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company’s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants, if any, and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company’s free standing derivatives consist of embedded conversion options with issued convertible notes. The Company evaluated these derivatives to assess their proper classification in the condensed consolidated balance sheets as of September 30, 2016 using the applicable classification criteria enumerated under ASC 815-Derivatives and Hedging. The Company determined that certain embedded conversion features do not contain fixed settlement provisions. The convertible notes contain a conversion feature such that the Company could not ensure it would have adequate authorized shares to meet all possible conversion demands. As such, the Company was required to record the debt derivatives which do not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period. Segment Reporting The FASB accounting guidance regarding disclosures about segments of an enterprise and related information establishes standards for the manner in which public business enterprises report information about operating segments. The Company is managed as a single operating segment for internal reporting and for internal decision making purposes. Therefore, we have concluded that we operate as a single segment. Recent Accounting Pronouncements Cash Flows In August 2016, the FASB issued ASU No. 2016-15 Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments, which addresses specific cash flow classification issues where there is currently diversity in practice including debt prepayment and proceeds from the settlement of insurance claims. ASU 2016-15 is effective for annual periods beginning after December 15, 2017, with early adoption permitted. The Company elected to early adopt ASU 2016-15 effective as of September 30, 2016. The adoption of ASU 2016-15 did not impact our results of operations or cash flows. In November 2016, the FASB issued ASU No. 2016-18 Statement of Cash Flows - Restricted Cash, which requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 is effective for annual periods beginning after December 15, 2017, with early adoption permitted. The Company elected to early adopt ASU 2016-18 including retrospective adoption for all prior periods. The impact of the adoption of ASU 2016-18 is the addition of a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet and was not material to the results. Cash The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of September 30, 2016 and 2015, the Company does not have any cash equivalents. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses are carried at amortized cost and represent liabilities for goods and services provided to the Company prior to the end of the financial year that are unpaid and arise when the Company becomes obliged to make future payments in respect of the purchase of these goods and services. Concentrations of Credit Risk The Company maintains deposits in a financial institution which is insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in this financial institution in excess of the amount insured by the FDIC. Research and Development The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic (“ASC”) 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. For the years ended September 30, 2016 and 2015, the Company’s expenditures on research and product development were $0 and $25,000 respectively. Comprehensive Income (Loss) The Company adopted ASC subtopic 220-10, Comprehensive Income (“ASC 220-10”) which establishes standards for the reporting and displaying of comprehensive income and its components. Comprehensive income is defined as the change in equity of a business during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. ASC 220-10 requires other comprehensive income (loss) to include unrealized gains and losses on available for sale securities adjustments. Income Taxes In March 2018, the FASB issued ASU 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118. ASC Topic 740 provides accounting and disclosure guidance on accounting for income taxes under generally accepted accounting principles (“U.S. GAAP”). This guidance addresses the recognition of taxes payable or refundable for the current year and the recognition of deferred tax liabilities and deferred tax assets for the future tax consequences of events that have been recognized in an entity’s financial statements or tax returns. FN1 ASC Topic 740 also addresses the accounting for income taxes upon a change in tax laws or tax rates. FN2 The income tax accounting effect of a change in tax laws or tax rates includes, for example, adjusting (or re-measuring) deferred tax liabilities and deferred tax assets, as well as evaluating whether a valuation allowance is needed for deferred tax assets. FN3 The guidance in ASC Topic 740 does not, however, address certain circumstances that may arise for registrants in accounting for the income tax effects of the Act. The staff understands from outreach that registrants will potentially encounter a situation in which the accounting for certain income tax effects of the Act will be incomplete by the time financial statements are issued for the reporting period that includes the enactment date of December 22, 2017. Questions have arisen regarding different approaches to the application of the accounting and disclosure guidance in ASC Topic 740 to such a situation. Accordingly, the SEC staff believes clarification is appropriate to address any uncertainty or diversity of views in practice regarding the application of ASC Topic 740 in situations where a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting under ASC Topic 740 for certain income tax effects of the Act for the reporting period in which the Act was enacted. The Tax Cuts and Jobs Act (the “Act”) changes existing United States tax law and includes numerous provisions that will affect businesses. The Act, for instance, introduces changes that impact U.S. corporate tax rates, business-related exclusions, and deductions and credits. The Act will also have international tax consequences for many companies that operate internationally. The Act has widespread applicability to registrants. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company adopted the provisions of ASC Topic 740-10, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of September 30, 2016 and 2015. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company classifies interest expense and any related penalties related to income tax uncertainties as a component of income tax expense. The Company did not record any income taxes during September 30, 2016. Advertising The Company’s advertising costs are expensed as incurred. Advertising expense was $0 and $600 for the years ended September 30, 2016 and 2015. Stock-Based Compensation In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in ASU 2016-09 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact that ASU 2016-09 will have on its consolidated financial statements and related disclosures. In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the consolidated financial statements and disclosures, but does not expect it to have a significant impact. Leases In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842) Leases (Topic 840) Business Combinations In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805) Clarifying the Definition of a Business” The amendments in this ASU clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted, including for interim or annual periods for which the financial statements have not been issued or made available for issuance. The Company adopted this guidance as of September 30, 2016. See Note 3 - Acquisitions In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact of adopting this standard on the consolidated financial statements and disclosures. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Sep. 30, 2016
Fair Value of Financial Instruments [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	NOTE 4 – FAIR VALUE OF FINANCIAL INSTRUMENTS The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable based on an entity’s own assumptions, as there is little, if any, related market activity (for example, cash flow modeling inputs based on assumptions) Financial liabilities as of September 30, 2016 measured at fair value on a recurring basis are summarized below: The Company determined that certain conversion option related to convertible notes issued did not have fixed settlement provisions and are deemed to be derivative financial instruments, since the exercise price was subject to adjustment based on certain subsequent equity transactions that would change the exercise price, the Company elected to use a lower reset provision. Accordingly, the Company was required to record such conversion option as a derivative liability and mark such derivative to fair value each reporting period. Such instrument was classified within Level 3 of the valuation hierarchy. For the purpose of calculating the potential embedded derivatives, the Company utilized an estimated conversion price of $0.05 (or $0.10 floor as is the case with one note) in estimating the fair value of the conversion option. The fair value of the conversion option was calculated using a binomial lattice formula with the following range of assumptions during the year ended September 30, 2016: At Inception September 30, 2016 Common Stock Estimated Fair Value $ 0.05 $ 0.05 to 0.15 Conversion Price per share 0.05-0.10 0.05-0.10 Conversion Shares 3,125,000 2,645,000 Call Option Value 0.0104 to 0.0226 0.006 to 0.11 Dividend Yield 0.00 % 0.00 % Volatility 120.00 % 120. to 133.7 % Risk-free Interest rate 0.68 % 0.26 to 0.36 % Contractual Term 0.75 to 1.00 years 0.27 to 0.69 years In the opinion of management, there is not a sufficient viable market for the Company’s common stock to determine its fair value, therefore management considers recent sales of its common stock to independent qualified investors and estimated fair value of net assets acquired through issuance of common stock. Since the valuation model inputs are not fixed, management has estimated the fair value to be utilizing a binomial lattice model. Considerable management judgment is necessary to estimate the fair value at each reporting period. Accordingly, actual results could vary significantly from management’s estimates. Conversion price per share and conversion shares are based on the lower of reset or floor price of the respective notes. The risk-free interest rate is the United States Treasury rate on the measurement date having a term equal to the remaining contractual life of the instrument. Since the Company’s stock has not been publicly traded with significant volume, the Company is utilizing an expected volatility based on a review of historical volatilities over a period of time equivalent to the expected life of the instrument being valued of similarly positioned public Companies within. The dividend yield is 0% as the Company has not made any dividend payment and has no plans to pay dividends in the foreseeable future. Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivative liabilities. Level 3 financial liabilities consist of the derivative liabilities for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. Significant observable and unobservable inputs include stock price, exercise price, annual risk free rate, term, and expected volatility, and are classified within Level 3 of the valuation hierarchy. An increase or decrease in volatility or interest free rate, in isolation, can significantly increase or decrease the fair value of the derivative liabilities. Changes in the values of the derivative liabilities are recorded as a component of other income (expense) on the Company’s condensed consolidated statements of operations and comprehensive loss. The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis for the year ended September 30, 2016: Balance - Beginning of period $ - Aggregate fair value of derivative instruments issued 142,604 Transfers out upon payoff of notes payable (52,389 ) Change in fair value of derivative liabilities 33,023 Balance - End of period $ 123,238

Investment in Equity Securities

Investment in Equity Securities	12 Months Ended
	Sep. 30, 2016
Investment in Equity Securities [Abstract]
INVESTMENT IN EQUITY SECURITIES	NOTE 5 – INVESTMENT IN EQUITY SECURITIES The fair values of the Company’s marketable securities are based on quoted market prices and are included in the accompanying consolidated balance sheet under total current assets as available-for sale securities. The Company relied on guidance by the FASB ASC 320-10-25-1 regarding a classification of securities. As of September 30, 2016, the Company’s available-for-sale securities consisted of 10,000,000 shares of Arrayit. (OTCB: ARYC) acquired in August 2014 in exchange for the issuance of 10,000,000 common shares of the Company. These shares were exchanged pursuant to a share exchange agreement with Arrayit in August 2014. The Company had previously determined that its investment was not classified as either trading securities or held to maturity. Furthermore, due to the liquidity profile of Arrayit shares as traded on the OTC Markets, the Company believed that it could liquidate such securities at any time; therefore these securities were classified as available-for-sale securities. These securities were recorded at fair market value with changes in value classified in the financial statements as unrealized gain/loss in other comprehensive income. Other than Temporary Decline in Available-for-Sale Securities In August 2015, new information came to the attention of Company management regarding its investment in Arrayit. The Arrayit shares went into a precipitous decline and had a de minims market value. Management of the Company believes that such decline was not due to an underlying condition of the Arrayit operations or business strategy and determined that such decline was probably not temporary due to the uncertainty of recovery of Arrayit’s share price in the short and long term. In reaching our conclusion, we relied on accounting guidance presented in ASC 320-10-35 regarding a subsequent measurement of available for sale securities and impairment and the temporary factors related thereto. Specifically, while the guidance could point to a decline that was temporary, management determined that the impact to the Arrayit shares had a minimal chance of recovery. The Company determined that its investment in available-for-sale securities had an other than temporary decline in value and chose to fully impair the value in our consolidated balance sheet as of September 30, 2015. The Company recorded a realized loss in the amount of $2,000,000 for the year ended September 30, 2015. Total loss from other-than-temporary impairment $ 2,000,000 Portion of loss previously recognized in other comprehensive income (400,000 ) Net impairment losses in the year ended September 30, 2015 $ 1,600,000 As of September 30, 2015, Arrayit was a significant stockholder of the Company. See Note 6.

License and Technology Agreemen

License and Technology Agreements	12 Months Ended
	Sep. 30, 2016
License and Technology Agreements [Abstract]
LICENSE AND TECHNOLOGY AGREEMENTS	NOTE 6 – LICENSE AND TECHNOLOGY AGREEMENTS The Company’s intangible assets consist of technology enhancements and licensing payments for its worldwide exclusive licensed rights to OvaDx Ò , a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. Technology Assignment Agreement with Arrayit Corporation On July 18, 2009, the Company entered into a Technology Assignment Agreement with Arrayit (the “Tech Transfer Agreement”), whereby Arrayit assigned to the Company, exclusively throughout the world, all right, title and interest in the technology behind the microarray-based test for the detection and monitoring of ovarian cancer (the “Intellectual Property). The consideration under the Tech Transfer Agreement for the Intellectual Property was 80% of the Company’s issued and outstanding shares of capital stock existing at the time of the agreement, or 19,350,000 shares of common stock. The term of the agreement is indefinite. Licensing Agreement with Wayne State University On December 7, 2009, the Company entered into a worldwide licensing agreement and sponsored research agreement with Arrayit and Wayne State University (“WSU”) in Detroit, Michigan, for the continued research and development of a protein microarray-based diagnostic test for the early detection of ovarian cancer. WSU’s research involving ovarian cancer has been focused on the specific expression of genes associated with ovarian cancer (the “License Agreement”). WSU has used Arrayit’s microarray technology to help identify key biomarkers using a process that has allowed them to isolate biomarkers unique to ovarian cancer. As a result, Arrayit has been able to build on this approach and is now in the late stage development phase of a simple blood test for the early detection of ovarian cancer that uses approximately 100 unique proteomic biomarkers in a microarray-based serologic detection of ovarian cancer markers that accumulate in the bloodstream as a result of the body’s natural immune response to developing ovarian tumors. WSU shall have the right to terminate the agreement if it reasonably determines that the Company is not diligently utilizing the licensed patents or the license agreement will expire as the patents expire. Under the terms of the License Agreement, the Company is obligated to make a one-time payment of $125,000 to WSU within 30 days after the approval of the first licensed product by the FDA or another comparable agency, and is obligated to make royalty payments of up to 5% of the net revenues of the licensed products on a quarterly basis, or minimum royalty payments as set forth below under the First Amendment. On March 1, 2014, the Company and WSU entered into an amendment to the License Agreement in order to reflect the new name of the Company and to amend certain provisions (the “First Amendment”) as follows: ● Update the list of licensed patents; ● Waive and update certain diligence milestones; ● Establish a payment schedule for certain past due patent costs due to WSU by the Company; ● Establish a payment schedule for certain accrued patent expenses incurred by WSU totaling $118,586; ● Require the Company to pay ongoing patent expenses; ● Waive the minimum royalty of $50,000 for each of 2011, 2012 and 2013 and adjust minimum annual royalties to $25,000 for 2014 and 2015, $50,000 for 2016 and 2017, $150,000 for 2018 and 2019 and $300,000 for 2020 and each year thereafter; ● Amend the list of material obligations; ● Waive certain interest and late fees; and ● Update addresses of record for both WSU and the Company. As of September 30, 2015, the carrying value of the rights to OvaDx Ò and payments to WSU under the License Agreement was $1,651,875, consisting of enhancements to the original initial rights licensed assigned to the Company resulting from the Tech Transfer Agreement with Arrayit as well as licensing payments made to WSU. The Company paid for these enhancements by the issuance of 10,000,000 common shares to Arrayit in August 2014, as well as cash payments to WSU. In 2015, the Company paid its clinical research organization $102,000 in conjunction with the commencement of the OvaDx to FDA trials. The Company will periodically assess the intellectual property status for changes in the valuation. The Company is not amortizing the value of the license. Upon FDA approval, the Company will be amortizing the license over the remaining term of the patent. As of September 30, 2015, the Company has commenced FDA approval process. As of September 30, 2015, the Company has not obtained final FDA approval and the asset has not been placed in service. Exclusive Services Agreement between Arrayit Corporation and the Company On September 10, 2009, the Company entered into an Exclusive Services Agreement with Arrayit (the “Services Agreement”), whereby the Company will utilize the services of Arrayit to manufacture and provide the Company with a commercial supply of a microarray-based test for the detection and monitoring of ovarian cancer. The term of the Services Agreement was for five (5) years, with election to extend by the Company for an additional five (5) year period. Thereafter, the Services Agreement shall renew automatically for successive two-year periods, unless either Arrayit or the Company notifies the other of its election not to renew at least twelve (12) months prior to the expiration of the term. The term has been extended through September 2019. On August 6, 2014, the Company and Arrayit agreed that, upon any sales of OvaDx Ò and if desired by the purchaser, that Arrayit would agree to include the manufacturing rights in the sale for no additional consideration.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Sep. 30, 2016
Convertible Notes Payable [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 7 – CONVERTIBLE NOTES PAYABLE January 2016 Convertible Note On January 5, 2016, the Company issued an unsecured convertible promissory note, in the principal amount of $112,500 which bears interest at 10% per annum and matures 9 months from the date of issuance. The total net proceeds the Company received from this note was $100,000, net of fees and original interest discount (“OID”) of $12,500. The note will be convertible at the option of the holder at any time into shares of common stock, at an initial conversion price equal to $0.35, subject to adjustment. In the event the market capitalization (as defined) falls below $10,000,000 at any time, then in such event (a) the initial conversion price for all conversions occurring after the first date of such occurrence shall equal the lower of the initial conversion price and the market price (as defined below) as of any applicable date of conversion, and (b) the true-up provisions described below shall apply to all conversions that occur after the first date the market capitalization falls below $10,000,000. The conversion price of the note is subject to full ratchet and anti-dilution adjustment for subsequent lower price issuances by the Company, as well as customary adjustments provisions for stock splits, stock dividends, recapitalizations and the like. Beginning on the six month anniversary of the closing date and continuing on the same day of each successive month thereafter, the Company must prepay $28,750, plus all accrued interest thereon, either in cash or in common stock, at the option of the Company (each, an “Installment Amount”). If the Note is prepaid in shares of common stock, such shares shall be issued at a 40% discount of the lowest closing bid price for the 20 consecutive trading days immediately preceding the applicable redemption date, subject to a floor of $0.10 (the “Market Price”). These certain conditions were deemed to be outside the Company’s control. The Company identified an embedded derivative related to a conversion option in the above described note. The accounting treatment of derivative financial instruments requires that the Company record the fair value of the derivative as of the inception date of the notes and to fair value the derivative as of each subsequent reporting date. At the inception of the notes, the Company determined the fair value of the embedded derivatives to be $11,669. For the sole purpose of calculating the potential embedded derivatives, the Company elected to use a lower reset or floor conversion price of $.05 and $0.10, respectively, to calculate the fair value. The Company booked such embedded derivatives as part of debt discount, and amortized through the term of the debt. February 2016 Amarantus Note, (Related Party) In connection with the acquisition of certain assets and assumption of certain liabilities of THI, the Company assumed and guaranteed a previously issued 8% convertible note (the “Note”) for $400,000 due February 28, 2017 to Shareholder. The Note is convertible at the option of the holder at any time into shares of THI’s common stock at $40.64 per share. The conversion price of the Note is subject to full ratchet and anti-dilution adjustment for subsequent lower price issuances by the Company, as well as customary adjustments provisions for stock splits, stock dividends, recapitalizations and the like. The Note was not modified upon assumption by the Company, accordingly the Company has determined that since the conversion option is not available should any demands be made by the Note holder, the note should be considered a non-convertible note for presentation and accounting purposes. The Company recorded $18,220 interest expense related to the Note during the year ended September 30, 2016. The Amarantus Note had $47,452 remaining debt discount as of September 30, 2016. At the inception of the notes, the Company determined the aggregate fair value of the embedded derivatives to be $87,037. For the sole purpose of calculating the potential embedded derivatives, the Company elected to use a lower reset or floor conversion price of $.05 and $0.10, respectively, to calculate the fair value. The Company booked such embedded derivatives as part of debt discount, and amortized through the term of the debt. March 2016 Amarantus Note (Related Party) On March 8, 2016, the Company issued a convertible promissory note (the “Amarantus Note”) with aggregate principal amount of $100,000 for an aggregate purchase price of $100,000. The Amarantus Note bears interest at 12% per annum and matures one year from the date of issuance. The Company recorded a total of $6,910 of interest expense for the year ended September 30, 2016. The Amarantus Note will be convertible at the option of the Investor at any time into shares of common stock, at an initial conversion price equal to $0.20, subject to certain anti-dilutive (reset) provisions. These anti-dilutive conditions were deemed to be outside the Company’s control. The Company identified an embedded derivative related to a conversion option in the Amarantus Note. The accounting treatment of derivative financial instruments requires that the Company record the fair value of the derivative as of the inception date of the notes and to fair value the derivative as of each subsequent reporting date. At the inception of the notes, the Company determined the aggregate fair value of the embedded derivatives to be $45,280. For the sole purpose of calculating the potential embedded derivatives, the Company elected to use a lower reset or floor conversion price of $.05 and $0.10, respectively, to calculate the fair value. The Company booked such embedded derivatives as part of debt discount, and amortized through the term of the debt. The Amarantus Note had $23,268 remaining debt discount as of September 30, 2016. The Company revalued the embedded derivatives associated with the Amarantus Note at $36,201 as of September 30, 2016, and recorded $19,290 gain from change in fair value of derivatives for the year ended September 30, 2016. On May 12, 2016, as part of the agreement with ADI, the Company has the right to offset the $100,000 promissory note due to Shareholder, for the assumption of certain liabilities and expenses in connection with the transaction. The Company has issued debt for which total proceeds were allocated to individual instruments based on the fair value of each instrument at the time of issuance. Such value of the debt was recorded a discount on debt and is being amortized over the term of the respective debt. For the year ended September 30, 2016 and 2015 amortization of debt discount was $22,012 and $-0-, respectively.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Sep. 30, 2016
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 8 – STOCKHOLDERS’ EQUITY Preferred Stock Effective January 27, 2015, the Company adopted an amendment to the articles of incorporation to authorize the issuance of preferred stock with preferences, limitations, and relative rights designated by our board of directors (the “Preferred Shares”). The amendment to our articles of incorporation will authorize the issuance of up to 50 million Preferred Shares, with different series under the discretion of our board of directors, without any action on the part of the stockholders. As of September 30, 2016 and 2015, no Preferred Shares are issued or outstanding. As discussed in Note 1, on December 29, 2014, the Company completed a merger with ALP. Upon consummation of the merger, the Series B Preferred Stock outstanding was retired whereby Arrayit became the majority shareholder. In connection with the merger, the Company’s former Chief Executive Officer entered into a voting agreement with Arrayit which granted the Company’s former Chief Executive Officer unilateral voting authority over Arrayit’s shares through December 2015. The Company’s former Chief Executive Officer is currently in the process of negotiating a renewal with Arrayit. No renewal at this time has been made. Common Stock On January 27, 2015, the Company filed an amendment to its Articles of Incorporation and effected a 17-for-1 reverse stock split of its issued and outstanding shares of common stock, whereby 109,939,000 outstanding shares of the Company’s common stock were converted into 6,467,000 shares of the Company’s common stock. The reverse stock split was effective in the market commencing on January 27, 2015. All per share amounts and number of shares in the consolidated financial statements, related notes and other items throughout have been retroactively restated to reflect the reverse stock split. During the year ended September 30, 2014, the Company issued an aggregate of 6,050,000 shares of our common stock for consulting services valued at $302,000. During the year ended September 30, 2014, the Company sold 800,000 shares of our common stock to certain investors for a total of $90,000. During the year ended September 30, 2014, the Company issued 10,000,000 shares of our common stock for intellectual property valued at $1,550,000. During the year ended September 30, 2014, the Company issued 10,000,000 shares of our common in exchange for 10,000,000 shares of Arrayit Corporation common stock valued at $2,000,000. The board of directors authorized the following issuances of stock for services. The Company evaluated in accordance with ASC 505-50 “Equity-Based Payments to Non-Employees”: During the three months ended December 31, 2014 the Company sold 2,781,666 shares of our common stock to certain investors for net proceeds of $340,000 inclusive of an aggregate of 15,000 shares of our common stock as a finder’s fee. On April 22, 2015, the Company issued an aggregate of 87,500 restricted shares of our common stock for as consideration for consulting services. During the year ended September 30, 2015, the Company expensed $7,125 relating to these services. On April 22, 2015, the Company issued an aggregate of 18,000 restricted shares of our common stock for as consideration for legal services. During the year ended September 30, 2015, the Company expensed $2,700 relating to these services. On April 22, 2015, the Company issued an aggregate of 100,000 restricted shares of our common stock to the two independent directors of the Company for their Board of Directors services. During the year ended September 30, 2015, the Company expensed $7,500 relating to these services. On September 15, 2015, the Company issued an aggregate of 1,200,000 restricted shares of our common stock for investor relations services valued at $180,000. These shares vest over a one-year service period. During the year ended September 30, 2015, the Company expensed $90,000 relating to these services. On September 15, 2015, the Company issued an aggregate of 250,000 restricted shares of our common stock for 6 months of social media and investor relations services valued at $37,500. These shares vest over a 6 month period. The services start in October 2015, accordingly during the year ended September 30, 2015, the Company did not record an expense. On September 15, 2015, the Company issued an aggregate of 60,000 restricted shares of our common stock for legal services valued at $9,000. These shares vest over a six month service period. During the year ended September 30, 2015, the Company expensed $4,500 relating to these services. On March 24, 2016, the Company issued an aggregate of 200,000 restricted shares of common stock to the two independent professionals to serve as Board of Directors for a fair value of $10,000. These shares vest over a one-year service period. On March 24, 2016, the Company issued an aggregate of 8,569,800 restricted shares of our common stock for satisfaction of certain accrued liabilities and payroll due to an officer aggregating $428,575. On May 5, 2016, the Company issued 200,000 restricted shares of common stock for a finder’s fee to a certain Director for a fair value of $10,000 On May 11, 2016, the Company issued 25,000,000 restricted shares of common stock to acquire certain net assets of THI for a fair value of $3,150,000. On May 11, 2016, the Company issued 80,000,000 restricted shares of common stock to acquire ADI for a fair value of $10,080,000. On August 24, 2016, the Company issued an aggregate of 2,000,000 restricted shares of common stock to a related party for professional services rendered during the year. During the year ended September 30, 2016, the Company sold 6,200,000 restricted shares of common stock to certain investors for a total of $310,000. During the year ended September 30, 2016, the Company issued an aggregate of 745,000 restricted shares of common stock for consulting services for a fair value of $49,750. An aggregate of 600,000 of these shares vest over a one-year period. During the year ended September 30, 2016, the Company issued an aggregate of 45,000 restricted shares of common stock for legal services for a fair value of $9,000. Stock Options and Warrants Warrants On March 10, 2015, in conjunction with the reverse recapitalization discussed in Note 1, Issuers Capital Advisors, LLC, an entity controlled by the Company’s former President and CEO, was granted 5,000,000 warrants with immediate vesting, a term of 5 years and an exercise price of $0.0001. These warrants were evaluated in accordance with ASC 718-20 “Stock compensation-award” since an officer and director controls the entity and were classified as equity. In March 2015, these warrants were exercised for cash proceeds of $500. The Company recorded the $641,126 fair value of these warrants as a cost of the merger. The fair value of the warrants on the issuance date was $0.128 per share, using recent sales to unaffiliated investors. The Company evaluated its past trading history and concluded that it is a thinly traded stock and that past cash sales to unaffiliated investors was the best measure of fair value. The Company determined the fair value of these warrants using the following (level 3 inputs): Stock price $ 0.128 Term (years) 2.5 Volatility 145 % Risk-free interest rate 1.62 % Exercise price $ 0.0001 Dividend yield 0.00 % On March 31, 2015, Issuer Capital Advisors, LLC, exercised 2,000,000 warrants with an exercise price of $0.0001 for cash proceeds of $200. As of September 30, 2016, the Company had no warrants issued and outstanding. The following table reflects a summary of common stock warrants outstanding and warrant activity during the periods: Number of Warrants Weighted Average Exercise Price Weighted Average Term (Years) Aggregate Intrinsic Value Warrants outstanding at September 30, 2014 2,000,000 $ 0.0001 4.9 $ - Granted 5,000,000 0.0001 5.0 - Exercised (7,000,000 ) 0.0001 4.9 - Forfeited - - - - Warrants outstanding and exercisable at September 30, 2015 - $ - - $ - Granted - - - - Exercised - - - - Forfeited - - - - Warrants outstanding and exercisable at September 30, 2016 - $ - - $ - The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company’s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between equity and liabilities is required. Stock Options On March 31, 2015, options for a total of 4,000,000 were exercised at $0.0001 per a cashless exercise into 3,882,352 shares of our common stock. On March 31, 2015, 6,000,000 options of our common stock were exercised for total proceeds of $600. Both of these options were exercised by Gregg Linn, the Company’s former Chief Executive Officer and President and Steven Scott, a former officer of the Company. Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the ASC. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. The fair value of stock-based payment awards during the years ended September 30, 2016 and 2015 was estimated using the Black-Scholes pricing model. The dividend rate is zero because the Company does not anticipate issuing dividends. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period. The Company estimated forfeitures related to option grants at a weighted average annual rate of 0% per year, as the Company does not yet have adequate historical data, for options granted during the years September 30, 2016 and 2015. As of September 30, 2016, the Company had no options issued and outstanding Stock option activity summary covering options is presented in the table below: Number of Options Weighted Average Exercise Price Weighted Average Term (Years) Aggregate Intrinsic Value Options outstanding at September 30, 2014 10,000,000 0.02 6.2 - Granted - - - - Exercised (9,882,352 ) (0.02 ) 5.8 - Forfeited (117,648 ) (0.05 ) 2.7 - Options outstanding and exercisable at September 30, 2015 - $ - - $ - Granted - - - - Exercised - - - - Forfeited - - - - Options outstanding and exercisable at September 30, 2016 - $ - - $ -

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2016
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES Legal In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. There are no such matters that are deemed material to the condensed consolidated financial statements as of September 30, 2016, except as discussed below. On January 13, 2014, Plaintiff Tamarin Lindenberg sued Arrayit, the Company, John Howell, Steven Scott and Gregg Linn in Civil Action No. L7698-13. Plaintiff alleged violations of the New Jersey Conscientious Employee Protection Act NJSA 34:19-1 to NJSA 34:19-8 (“CEPA”), breach of contract, breach of covenant of good faith and fair dealing, economic duress and intentional infliction of emotional distress. On August 6, 2014, the District Court dismissed Plaintiff’s complaint against Arrayit for failure to state a claim upon which relief may be granted and against John Howell for lack of jurisdiction. The Company and its officers remain as defendants in the action. The Company and its officers have mounted a vigorous defense against these claims and believe they are without legal merit. As of the date of this filing, a range of potential loss is not estimable. Employment Agreements On October 1, 2014, we entered into an employment agreement with Gregg Linn, our Chief Executive Officer. The employment agreement provide that Mr. Linn will receive an annual base salary of $240,000 per year. In addition, Mr. Linn is entitled to monthly car allowance of $1,500 and the Company has agreed to pay to Mr. Linn the greater of 100% of all health care premiums of $3,000 per month. Mr. Linn was entitled to participate in any and all benefit plans, from time to time, in effect for senior management, along with vacation, sick and holiday pay in accordance with the Company’s policies established and in effect from time to time. The employment agreement provides for termination of Mr. Linn’s employment without any further obligation on our part upon the death or disability of the executive or for cause. In the event that an executive’s employment is terminated for good reason, we are obligated to pay Mr. Linn his base salary for a twelve month period beginning on the date of termination and any pro-rated potion of any bonus payable to Mr. Linn, which shall be assumed to be 30% of his base compensation unless otherwise provided for by the board of directors. The employment agreements also contain covenants (a) restricting the executive from engaging in any activity competitive with our business during the term of the employment agreement and in the event of termination for cause or without good reason, for a period of eighteen months thereafter, (b) prohibiting the executive from disclosing confidential information regarding us, and (c) soliciting our employees, customers and prospective customers during the term of the employment agreement and for a period of eighteen months thereafter.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 – RELATED PARTY TRANSACTIONS The Company leases corporate office space under a month-to-month operating lease of $200 per month from an entity controlled by the Company’s former Chief Executive Officer. For the year ended September 30, 2016 and September 30, 2015, total rent expense was $18,400 and $2,400, respectively. The Company had accrued expenses due to current and former officers, consisting mainly of salary. As of September 30, 2016 and September 30, 2015, accrued expenses due to officers were $256,480 and $141,717, respectively. The following selling, general and administrative expenses for the year ended September 30, 2016 were incurred by Greg Linn, the Company’s former CEO: For the year ended Auto Allowances $ 18,000 Salaries and wages 240,000 Insurance Expense 36,000 Payroll Expenses 16,190 Travel Expenses 21,484 Total $ 331,674 During the year ended September 30, 2016, Steve Scott, former CEO, incurred $17,500 of consulting and settlement expenses. During the year ended September 30, 2016, Michael Linn, former consultant, incurred $23,450 of salary and professional fees. During the year ended September 30, 2016, certain former Directors incurred Directors Fees in the sum of $12,500.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2016
Income Taxes [Abstract]
INCOME TAXES	NOTE 11 – INCOME TAXES The tax effects of temporary differences that give rise to deferred tax assets are presented below: For The Years Ended 2016 2015 Deferred Tax Assets: Net operating loss carryforward $ 5,412,924 $ 799,560 Stock-based compensation 497,325 - Marketable Securities - 788,000 Total deferred tax assets 5,910,249 1,587,560 Valuation allowance (5,910,249 ) (1,587,560 ) Deferred tax asset, net of valuation allowance $ - $ - Changes in valuation allowance $ (4,322,689 ) $ (17,440 ) The income tax provision (benefit) consists of the following: For The Years Ended 2016 2015 Federal: Current $ - $ - Deferred 3,730,054 15,049 State and local: Current - - Deferred 592,632 2,391 4,322,689 (17,440 ) Change in valuation allowance (4,322,689 ) (17,440 ) Income tax provision (benefit) $ - $ - A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: For The Years Ended 2016 2015 Tax benefit at federal statutory rate (34.0 )% (34.0 )% State tax, net of federal benefit - % (1.04 )% Permanent differences - % 0.02 % True up of deferred tax asset - % 34.49 % Change in valuation allowance 34.0 % 0.53 % Effective income tax rate 0 % 0 % The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company’s history of losses since inception, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized. At September 30, 2016 and 2015, the Company had $13,738,387 and $2,029,517, respectively, of both federal and state net operating losses that may be available to offset future taxable income. The net operating loss carry forwards, if not utilized, will expire 20 years from the filing of the Company's federal returns. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company's net operating loss carry forwards are subject to annual limitations in the event of a greater than 50% ownership change. The Company anticipates filing income tax returns in the U.S. federal and Arizona jurisdictions and such returns will be subject to examination by taxing authorities, when filed. The Company has not filed any income taxes to date.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS On September 19, 2017, the Company and Memory Dx, LLC entered into a second amended and restated settlement agreement pursuant to which in consideration for fully satisfying the Default Judgment, the Company agreed to provide MDX the following: (i) an aggregate of $250,000 (the “Cash Consideration”) payable as follows: (i) $35,000 which has been previously paid, (ii) $3,500 which was paid upon execution of the agreement (iii) $2,000 which will be payable on the last calendar day of each month for October and November 2017, (iv) $5,000 which will be payable on the last calendar day for December 2017 and each of January and February 2018 and (v) $10,000 which will be payable on the last calendar day of each month until the full consideration is paid. Notwithstanding the foregoing, upon the sale by the Company of its equity securities in a single offering for aggregate gross proceeds of at least $7,500,000 (the “Qualified Offering”) after the date of the agreement, the Company will pay any remaining amount of the Cash Consideration then outstanding upon the final closing of such Qualified Offering. The Company previously issued to MDX 5,000,000 restricted shares of common stock (the “Initial Shares”) on or prior to the date of the amended agreement as partial consideration for the Default Judgment. In addition, the Company agreed to issue MDX an additional 5,000,000 restricted shares of common stock (the “Additional Shares”). Within three (3) business days of the issuance of the Additional Shares, MDX shall take all necessary action to withdraw the recorded Default Judgment. The Default Judgment shall be set aside without prejudice. Upon a default of the obligations to timely pay the Cash Consideration, after written notice and five (5) business days to cure, MDX will be entitled to reinstate the Default Judgment. MDX shall assign the License Agreement between MDX and University of Leipzig dated May 22, 2013, as amended, to the Company, as well as assign the Asset Purchase Agreement between MDX and AMBS to the Company upon final settlement of this matter. Between October 28, 2016 and November 7, 2016, the Company entered into a various convertible promissory notes (collectively, the “Oct 2016 Notes”) with accredited investors (the “October 2016 Investors”) pursuant to which the October 2016 Investors purchased an aggregate principal amount of $65,000 of Convertible Promissory Notes for an aggregate purchase price of $65,000. The Oct 2016 Notes bear interest at 12% per annum and mature on six months from the date of issuance. The Oct 2016 Notes will be convertible at the option of the holder at any time into shares of common stock, at an initial conversion price equal to the lesser of (i) $0.25 or (ii) the closing sales price of such common stock on the date of conversion, subject to adjustment. Between November 16, 2016 and January 3, 2017, the Company entered into various convertible promissory notes (collectively, the “Nov 2016 Notes”) with accredited investors (the “Nov 2016 Investors”) pursuant to which the Nov 2016 Investors purchased an aggregate principal amount of $786,500 of Original Issue Discount Senior Secured Convertible Notes for an aggregate purchase price of $605,000. The Nov 2016 Notes bear interest at 8% and mature on January 15, 2018. The Nov 2016 Note will be convertible at the option of the holder at any time into shares of common stock, at an initial conversion price equal to $0.15, subject to adjustment. On November 28, 2016, the Company entered into a Binding Letter of Intent (the “Binding LOI”) with Prism Health Dx, Inc. (“PHDX”) for a business combination transaction wherein the Company agreed to issue such number of shares of common stock equal to 50% of the post-transaction outstanding shares of the Company to the shareholders of PHDX in exchange for the acquisition of 100% of the outstanding common stock of PHDX. At the time, the Company and PHDX entered into the Binding LOI, Mr. Philippe Goix was the President & CEO of PHDX. The Binding LOI contained exclusivity provisions wherein PHDX agreed not to enter into negotiations or discussions with third parties regarding similar transactions for a period of 90 days from the date of the Binding LOI (the “Exclusivity Period”). Concurrently with the execution of the Binding LOI, the Company agreed to lend PHDX an aggregate of $200,000, which was evidenced by a promissory note that bears interest at 5% per annum and matures one year from the date of issuance to support PHDX’s ongoing working capital needs to complete the transaction (the “Bridge Note”). The transaction was not consummated within the Exclusivity Period and the parties are no longer pursuing the transaction. The Binding LOI was canceled in March 2017 and companies did not consummate the contemplated business combination transaction. On January 25, 2017, the Company entered into an Exchange Agreement (the “Exchange Agreement”) with Gregg Linn, the Company’s chief executive officer (the “Executive”). Pursuant to the terms of the Exchange Agreement, the Company agreed to issue 3,000 shares of the Company’s series B preferred stock (the “Preferred Stock”) in exchange for the cancellation of $98,000 in accrued but unpaid compensation owed to the Executive. The Preferred Stock was offered and sold pursuant to an exemption from the registration requirements provided by Section 3(a)(9) of the Securities Act of 1933, as amended. On April 26, 2017, the Company’s license to MSPrecise® from the University of Texas Southwestern (“UTSW”) was terminated due to non-compliance with certain diligent prosecution provisions under the license (“Terminated License”). The Company maintains full ownership over significant intellectual property in the form of patents, patent applications, know-how and data that it believes will limit the UTSW’s, or a future licensor’s, freedom to operate (“Limiting IP”) in commercializing MSPrecise in the form in which it has been clinically tested to date. The Company has informed UTSW of the Company’s Limiting IP, as well as the Company’s desire to regain certain commercial rights previously granted under the Terminated License. On June 2, 2017, the Company entered into a Separation and Release Agreement (the “Separation Agreement”) with Gregg Linn, the Company’s former Chief Executive Officer, pursuant to which Mr. Linn’s status as chief executive officer and director of the Company ended effective June 2, 2017. Pursuant to the Agreement, the Company shall (a) pay Mr. Linn a lump sum cash payment of $30,000 upon on the Effective Date (as defined in the Agreement), (b) reimburse Mr. Linn for expenses paid on behalf of the Company, $2,500 of which will be paid on the Effective Date and $2,978.41 to be paid out of the proceeds of the first closing of the next financing of the Company’s equity and/or debt securities to be consummated after the completion of the Financing and (c) upon the earliest occurrence of a Triggering Event (as defined in the Separation Agreement), the Company shall pay Mr. Linn a lump sum cash payment of $180,000 within three (3) business days of the date a Triggering Event occurs. In addition, the Company shall issue Mr. Linn 15,000,000 restricted shares of the Company’s common stock (“Equity Issue”) which Equity Issue shall vest quarterly over three (3) years from the termination date in accordance with the terms of that certain restricted stock award agreement. All shares of common stock currently held by Mr. Linn, including the Equity Issue, shall be subject to the terms of that certain lockup agreement, dated May 11, 2016. Finally, Mr. Linn was granted “piggyback” registration rights, subject to certain exceptions, to include on the next registration statement the Company files with SEC for a primary offering (excluding any securities to be included on Form S-4 or S-8) of its equity securities (or on the subsequent registration statement if such registration statement is withdrawn) such number of shares of the Company’s common stock held by Mr. Linn and/or his assigns equal to eight percent (8%) of the aggregate value of the securities to be included on such registration statement, subject to certain limitations. Pursuant to the Agreement, Mr. Linn has agreed to comply with the confidential information and noncompetition and non-solicitation provisions in the Executive Employment Agreement dated October 1, 2014 between Mr. Linn and the Company. On June 19, 2017, the Company entered into a securities purchase agreement (the “Agreement”) with an accredited investor (the “June 2017 Investor”) pursuant to which the June 2017 Investor purchased a Senior Secured Convertible Note for an aggregate purchase price of $325,000 (the “June 2017 Note”). The June 2017 Notes bear interest at 8% and mature thirty-six months from the date of issuance. The June 2017 Notes will be convertible at the option of the holder at any time into shares of common stock, at an initial conversion price equal to $0.06 per share, subject to adjustment (“June 2017 Initial Conversion Price”). Upon an investment of an additional $75,000 by the June 2017 Investor or another financier approved by the June 2017 Investor, bringing the total investment under the terms of the June 2017 Note to a minimum of $400,000, the Preferred Stock issued pursuant to the Exchange Agreement described above shall be cancelled. In connection with the Agreement, the June 2017 Investor received an aggregate of 650,000 shares of common stock (the “June 2017 Commitment Shares”), a warrant to purchase such number of shares of common stock equal to 200% of their subscription amount divided by the June 2017 Initial Conversion Price (the “June 2017 Warrant”) and a purchase right to purchase such number of shares of common stock equal to 800% of their subscription amount divided by the June 2017 Initial Conversion Price (the “June 2017 Right”). The June 2017 Note, June 2017 Commitment Shares, June 2017 Warrant and June 2017 Purchase Right are collectively referred to herein as the “June 2017 Investment”. The June 2017 Warrant is exercisable for a period of five years from the date of issuance at an initial exercise price of $0.06. The June 2017 Right is exercisable beginning on the eighteen (18) month anniversary of the date of issuance until the five-year anniversary of the date of issuance at an initial exercise price of $0.06. The securities purchase agreement entered into with the June 2017 Investor limited the size of the June 2017 Investment to a total of $750,000. On June 20, 2017, the board of directors of the Company added Philippe Goix, PhD, MBA as chief executive officer of the Company, effective immediately. The Company entered into an offer letter dated June 20, 2017 (the “Offer Letter”) with Dr. Goix. The Offer Letter has no specified term, and Dr. Goix’s employment with the Company will be on an at-will basis. Dr. Goix’s employment with the Company will commence on June 20, 2017 (the “Start Date”). Base Salary and Bonus. Sign-on Bonus. Performance Bonus. Equity Compensation Other Benefits and Terms. On or about April 24, 2017, John G. Hartwell (“Hartwell”) and Corrine Ramos (“Ramos” and collectively with Hartwell, the “Plaintiffs”) filed a lawsuit against the Company, Avant Diagnostics Acquisition Corp. and Gregg Linn (collectively the “Defendants”) in the Circuit Court for Montgomery County, Maryland (Case Number 432180-V) (the “MD Court”), On or about June 8, 2017, the parties entered into a settlement agreement pursuant to which the Company agreed to pay Defendants an aggregate of approximately $154,000 in installments as set forth in the agreement. The first payment of $29,819.99 was made by the Defendants to Plaintiffs on or about July 10, 2017. As a result of the first payment being made pursuant to the agreement, Plaintiffs dismissed the action against the Defendants without prejudice on or about July 13, 2017. On July 3, 2017 the Company entered into a settlement agreement with PHDX with respect to The Bridge Note wherein PHDX repaid $100,000 to the Company in exchange for the extinguishment of the Bridge Note. On July 6, 2017, the Company entered into a satisfaction of note (the “Satisfaction of Note”) with Black Mountain Equity Partners LLC, the holder of a promissory note in the aggregate principal amount of $25,000 (the Black Mountain Note”) Pursuant to the terms of the Satisfaction of Note, the Company agreed to pay off the Black Mountain Note for an aggregate principal amount of $25,000 by August 1, 2017 (the Black Mountain Settlement”) and 62,500 common stock. The parties have agreed to extend the payment of the Settlement Amount until October 31st, 2017. On July 14, 2017, the Company entered into an Exchange Agreement (the “Coastal Exchange Agreement”) with Coastal Investment Partners, LLC. Prior to the execution of the Coastal Exchange Agreement, the Company agreed to exchange the principal amount due under the convertible promissory note issued July 6, 2016 plus accrued but unpaid interest and default and other amounts due and payable under such notes (the “July 2016 Notes”) in exchange for the issuance of new convertible promissory notes due January 15, 2018 in the aggregate principal amount of $380,250.00, which new notes are on substantially similar terms to the Nov 2016 Notes (the “New Coastal51 Note”). Pursuant to the terms of the Coastal Exchange Agreement, the Company and Coastal agreed to exchange the New Coastal51 Notes for the issuance of new convertible promissory notes due July 14, 2019 in the aggregate principal amount of $442,325.00, (the “New Coastal Note”). In connection with the Coastal Exchange Agreement, the Company and the investor agreed to a binding letter of intent whereby the Company agreed, to among other things, upon getting current and releasing the New Coastal Note from escrow to issue the investor 750,000 shares of the Company’s common stock related to an adjustment that resulted under the July 2016 Notes because of the issuance of the Nov 2016 Notes and the Company agreed to get current in its ongoing reporting requirements with the Securities and Exchange Commission within 90 days of the execution of the Coastal Exchange Agreement. If the Company does not get current within the 90-day period, the New Coastal Notes are null and void and shall revert back to the Coastal51 Notes issued to the investors. The notes issued to Coastal are secured by a first priority security interest to Coastal in the Company’s Equipment Assets (as defined in the pledge agreement) and a second prior security interest in the Company’s Intellectual Property Assets (as defined in the pledge agreement), all which are currently owned by the Company pursuant to the terms of that certain pledge and security agreement, entered into in connection with the Coastal Exchange Agreement. New Coastal Notes were offered and sold pursuant to an exemption from the registration requirements provided by Section 3(a)(9) of the Securities Act. On July 14, 2017, the Company exchanged an aggregate of $375,000 in contingent liabilities owed to AMBS in exchange for 6,250,000 shares of the Company’s common stock. On July 28, 2017, the Company entered into an Exchange Agreement (the “October 2016 Investors Exchange Agreement”) with the October 2016 Investors. Pursuant to the terms of the October 2016 Exchange Agreement, the Company agreed to exchange the principal amount due under the convertible promissory notes issued to the October 2016 Investors plus other amounts due and payable under such notes in exchange for the issuance of new convertible promissory notes due July 28, 2019 in the aggregate principal amount of $51,200 (the “New October 2016 Notes”). In connection with the October 2016 Investors Exchange Agreement, the Company and the investors agreed to a binding letter of intent whereby the Company agreed, to among other things, the Company agreed to get current in its ongoing reporting requirements with the Securities and Exchange Commission within 120 days of the execution of the October 2016 Investors Exchange Agreement. If the Company does not get current within the 120-day period, the New October 2016 Notes are null and void and shall revert back to the original notes issued to the investors. In connection with the issuance of the New October 2016 Notes, the October 2016 Investors agreed to waive all accrued interest and penalties related to the October 2016 Notes, upon getting current and releasing from escrow to issue through the execution date of the exchange for the purchase an aggregate of 793,390 shares of the Company’s common stock, which shares shall be kept by the October 2016 Investors whether or not the Company meets its conditions under the letter of intent. The New October 2016 Notes were offered and sold pursuant to an exemption from the registration requirements provided by Section 3(a)(9) of the Securities Act. On August 8, 2017, the Company entered into a securities purchase agreement with an accredited investor (the “August 2017 Investor”) pursuant to which the August 2017 Investor purchased $75,000 of the June 2017 Investment for an aggregate purchase price of $75,000 (the “August 2017 Investment”). The June 2017 notes bear interest at 8% and mature thirty-six months from the date of issuance. The June 2017 Notes will be convertible at the option of the holder at any time into shares of common stock, at an initial conversion price equal to $0.06 per share, subject to adjustment (“June 2017 Initial Conversion Price”). In connection with the Agreement, the August 2017 Investor received an aggregate of 150,000 shares of common stock as commitment shares, a warrant to purchase such number of shares of common stock equal to 200% of their subscription amount divided by the June 2017 Initial Conversion Price and a purchase right to purchase such number of shares of common stock equal to 800% of their subscription amount divided by the June 2017 Initial Conversion Price. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $0.06. The Purchase right is exercisable beginning on the eighteen (18) month anniversary of the date of issuance until the five-year anniversary of the date of issuance at an initial exercise price of $0.06. On August 25, 2017, the Company entered into a securities purchase agreement with the June 2017 Investor pursuant to which the June 2017 Investor purchased $50,000 of the June 2017 Investment for an aggregate purchase price of $50,000 (the “August 2017 Investment”). The June 2017 notes bear interest at 8% and mature thirty-six months from the date of issuance. The June 2017 Notes will be convertible at the option of the holder at any time into shares of common stock, at the June 2017 Initial Conversion Price. In connection with the agreement, the June 2017 Investor received an aggregate of 100,000 shares of common stock as commitment shares, a warrant to purchase such number of shares of common stock equal to 200% of their subscription amount divided by the June 2017 Initial Conversion Price and a purchase right to purchase such number of shares of common stock equal to 800% of their subscription amount divided by the June 2017 Initial Conversion Price. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $0.06. The purchase right is exercisable beginning on the eighteen (18) month anniversary of the date of issuance until the five-year anniversary of the date of issuance at an initial exercise price of $0.06. On August 25, 2017 the Company entered into a binding letter of intent with the June 2017 Investor and the August 2017 Investor (the “Investors”) whereby the parties agreed that the offering documents would be amended to add an additional conversion feature wherein the June 2017 Investment could be exchanged and/or converted into a class of the Company’s preferred stock to be created (the “Preferred Stock”) that is convertible into the equivalent of 49.99% of the then outstanding common stock of the Company pro-rata on an as converted basis based upon a total investment of $750,000 into the June 2017 Investment. The Preferred Stock shall also have the right to vote alongside the common stock on an as converted basis. The ability of the Investors to convert the June 2017 Investment into Preferred Stock is subject to the execution of definitive documentation between the parties. As of September 5, 2017, exactly $525,000 has been invested into the June 2017 Investment. On August 25, 2017, the Board of Directors accepted the resignation of Gerald Commissiong from the Board of Directors of the Company, effective immediately. On August 25, 2017, the board of directors of the Company added Philippe Goix, PhD, MBA as a director of the Company, effective immediately. On September 5, 2017, the Company entered into a securities purchase agreement with an accredited investor (the “September 2017 Investor”) pursuant to which the September 2017 Investor purchased $75,000 of the June 2017 Investment for an aggregate purchase price of $75,000 (the “September 2017 Investment”). The June 2017 notes bear interest at 8% and mature thirty-six months from the date of issuance. The June 2017 Notes will be convertible at the option of the holder at any time into shares of common stock, at the June 2017 Initial Conversion Price. In connection with the agreement, the September 2017 Investor received an aggregate of 150,000 shares of common stock as commitment shares, a warrant to purchase such number of shares of common stock equal to 200% of their subscription amount divided by the June 2017 Initial Conversion Price and a purchase right to purchase such number of shares of common stock equal to 800% of their subscription amount divided by the June 2017 Initial Conversion Price. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $0.06. The purchase right is exercisable beginning on the eighteen (18) month anniversary of the date of issuance until the five-year anniversary of the date of issuance at an initial exercise price of $0.06. On September 13, 2017, the Company filed a Certificate of Withdrawal of Certificate of Designations (the “Certificate of Withdrawal”) with the Nevada Secretary of State. The Certificate of Withdrawal eliminates the Company’s Series B Preferred Stock, par value $0.001 per share, from the Company’s articles of incorporation, as amended. No shares of the Series B Preferred Stock were outstanding at the time of filing of the Certificate of Withdrawal. On October 6, 2017, the Company entered into a securities purchase agreement with the June 2017 Investor pursuant to which the June 2017 Investor purchased $20,000 of the June 2017 Investment for an aggregate purchase price of $20,000 (the “October 2017 Investment”). The June 2017 notes bear interest at 8% and mature thirty-six months from the date of issuance. The June 2017 Notes will be convertible at the option of the holder at any time into shares of common stock, at the June 2017 Initial Conversion Price. In connection with the agreement, the June 2017 Investor received an aggregate of 40,000 shares of common stock as commitment shares, a warrant to purchase such number of shares of common stock equal to 200% of their subscription amount divided by the June 2017 Initial Conversion Price and a purchase right to purchase such number of shares of common stock equal to 800% of their subscription amount divided by the June 2017 Initial Conversion Price. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $0.06. The purchase right is exercisable beginning on the eighteen (18) month anniversary of the date of issuance until the five-year anniversary of the date of issuance at an initial exercise price of $0.06. On December 4, 2017, the Company accepted the resignation of Philippe Goix as the Company’s chief executive officer and director, effective immediately. On December 15, 2017, the Company entered into a Separation and Release Agreement (the “Goix Separation Agreement”) with Philippe Goix, the Company’s former Chief Executive Officer, pursuant to which Dr. Goix’s status as chief executive officer and director of the Company ended effective December 4, 2017. Pursuant to the Goix Separation Agreement, upon the occurrence of a Triggering Event (as defined in the Goix Separation Agreement), the Company shall pay Dr. Goix a lump sum cash payment of $27,346.84 within three (3) business days of the date such Triggering Event occurs. On March 30, 2018, the Company entered into an Asset Purchase Agreement (the “ Purchase Agreement AMBS Exchange Agreement Transaction Consideration On May 25, 2018 (the “Effective Date”), Avant Diagnostics, Inc. (the “Company”) entered into securities purchase agreements (collectively, the “Purchase Agreement”) with accredited investors (the “Investors”) pursuant to which the Company sold an aggregate of six hundred and fifty thousand (650,000) shares of its series A convertible preferred stock for aggregate gross proceeds of $650,000 (the “Series A Preferred Stock”). In addition, existing debtholders of the Company exchanged an aggregate of $516,155 (currently due and payable under existing indebtedness) for an aggregate of 516,155 shares of Series A Preferred Stock pursuant to exchange agreements described below. The terms of the Series A Preferred Stock are set forth under Item 3.02 below. For a period of one year from the date of final closing of the offering, Investors holding at least a majority of the Series A Preferred Stock outstanding from time to time shall have the right to cause the Company to sell for cash to such Investors on a pro rata At any time on or after the Effective Date and until the Company’s 2019 annual meeting of stockholders, the Investors, jointly and severally, shall have the exclusive right, voting separately as a class, to elect up to six (6) directors (each director, an “Investor Director”). A Preferred Director so elected shall serve for a term of one year and until his successor is elected and qualified. An Investor Director may, during his or her term of office, be removed at any time, with or without cause, by and only by the affirmative vote, at a special meeting of holders of Series A Preferred Stock called for such purpose. Any vacancy created by such removal may also be filled at such meeting or by such consent for the remainder of such initial one year term. At any time on or after the Effective Date and until the Company’s 2019 annual meeting of stockholders, Infusion 51a, LP (“Infusion”) shall have the right to elect up to three (3) directors (each director, an “Infusion Director”). An Infusion Director so initially elected shall serve for a term of one year and until his successor is elected and qualified. Any vacancy in the position of an Infusion Director may be filled only by the affirmative vote of Infusion. An Infusion Director may, during his or her term of office, be removed at any time, with or without cause. Any vacancy created by such removal may also be filled by Infusion for the remainder of such initial one year term. As soon as practicable after the final closing of the offering, the Company shall use commercially reasonable efforts to take all necessary actions and to obtain such approvals of the Company’s stockholders as may be required to increase the Company’s authorized shares of Common Stock such that the Company can issue all of the shares of Common Stock issuable upon completion of the restructuring and undertake a reverse stock split at such ratio where the number of shares of Common Stock outstanding after consummation of such reverse stock split shall be approximately 15,000,000 shares (the “Reverse Split”) before the exchange of the Series A Preferred Stock into shares of common stock (the “Stockholder Approval”). Until the consummation of the Reverse Split (as defined herein), the Investors appointed AVDX Investors Group LLC (the “Investor Representative”) as its attorney-in-fact for the purpose of carrying out the Stockholder Approval. On the Effective Date, the Company entered into a Consulting Agreement (the “Agreement”) with Investor Representative. Under the Agreement, the Investor Representative shall perform such consulting and advisory services, within Investor Representative’s area of expertise, as the Company or any of its subsidiaries may reasonably require from time to time. During the six-month term of the Agreement, Jeff Busch shall perform the services on behalf of Investor Representative (“Designated Person”). The Agreement has an initial term of six months from the date of execution and shall automatically renew on a monthly basis unless either party gives notice of non-renewal to the other party at least fifteen days prior to the date of the Agreement, provided this agreement shall not extend beyond 12 months from the date of the Agreement. Pursuant to the Agreement, the Company shall pay Investor Representative an annual amount of $160,000, payable either in cash or Series A Preferred Stock (or Common Stock upon filing of the Charter Amendment and consummation of the Reverse Split) during the term of the Agreement (the “Base Compensation”). The Company shall promptly reimburse Investor Representative for all travel, meals, entertainment and other ordinary and necessary expenses incurred by Investor Representative in the performance of its duties to the Company. Investor Representative’s and Designated Person’s position with the Company may be terminated at any time, with or without cause or good reason, upon at least 30 days prior written notice. During the term of the Agreement and for a period of twelve months thereafter, Investor Representative and Designated Person will be subject to non-competition and non-solicitation provisions, subject to standard exceptions. Investors will also provide Investor Representative an irrevocable proxy to vote their shares on all corporate matters until completion of the Reverse Split. From the Effective Date until the consummation of the Reverse Split, upon any issuance by the Company of common stock or Common Stock Equivalents (as defined in the Series A Certificate of Designations (as defined below)) for cash consideration, indebtedness or a combination of units thereof (a “Subsequent Financing”), each Qualifying Purchaser (as defined below) shall have the right to participate in up to an amount of the Subsequent Financing equal to 50% of the Subsequent Financing on the same terms, conditions and price provided for in the Subsequent Financing. For purposes herein, “Qualifying Purchaser” means an Investor with a subscription amount of at least $150,000. Beginning on the six month anniversary of the final closing of the offering, on or prior to the sixtieth (60th) calendar day after the date of receipt of written demand from Investors holding at least 51% of Registrable Securities (as defined in the Purchase Agreement), the Company shall prepare and file with the Securities and Exchange Commission (the “SEC”) a registration statement covering the resale of all of the Registrable Securities that are not then registered on an effective registration statement. In connection with the offering, we agreed to pay our placement agent, a registered broker-dealer, or the Placement Agent, (i) a cash commission of 8% of the gross proceeds raised from investors in the offering, and to issue to the Placement Agent warrants to purchase a number of shares of common stock equal to 4% of the gross proceeds divided by the respective offering price, with a term of seven years from the date of issuance. On the Effective Date, the Company entered into an exchange agreement (collectively, the “2017 Investors Exchange Agreement”) with the investors who purchased convertible promissory notes between June 2017 and October 2017 (the “2017 Notes”) for an aggregate principal amount of $545,000 (the “2017 Investors”). Pursuant to the terms of the 2017 Investors Exchange Agreement, the Company agreed to exchange (i) the principal amount due under the 2017 Notes (ii) warrants to purchase 18,166,667 shares of common stock and (iii) purchase rights to purchase shares of common stock for an aggregate of 72,666,667 shares of common stock, in exchange for an aggregate approximately 22,290,800 shares of series B convertible preferred stock having an aggregate value of $545,000 (the “Series B Preferred Stock”). The 2017 Investors hav

Significant Accounting Polici19

Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2016
Significant Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Theranostics Health, Inc. and Amarantus Diagnostics Inc. All intercompany transactions and balances have been eliminated in consolidation.
Acquisitions	Acquisitions Amarantus Diagnostics, Inc. On May 11, 2016, the Company entered into a Share Exchange Agreement (the “Exchange Agreement”) with Shareholder to purchase 100% of the outstanding capital stock of ADI (the “ADI Acquisition”). The Company paid an aggregate consideration of 80,000,000 shares of its common stock and a $50,000 convertible promissory note for the ADI Acquisition, subject to the issuance of additional shares upon the occurrence of certain events set forth in the Share Exchange Agreement. Each share of Avant common stock issued in connection with the ADI Acquisition shall be subject to a lock-up beginning on the May 11, 2016 and ending on the earlier of (i) eighteen (18) months after such date or (ii) a Change in Control (as defined in the Exchange Agreement) or (iii) written consent of the parties that certain escrow agreement entered into between the Company, ADI, the Shareholder and certain creditors of the Shareholder. The convertible promissory note issued bears interest at 12% per annum and matures one year from the date of issuance. The note will be convertible at the option of the Investor at any time into shares of common stock, at an initial conversion price equal to $0.20, subject to adjustment. On May 12, 2016, as part of the agreement with ADI, the Company has the right to offset the $100,000 promissory note due to Shareholder, for the assumption of certain liabilities and expenses in connection with the transaction. A summary of consideration is as follows: 80,000,000 shares of the Company’s common stock $ 10,080,000 Total purchase price 10,080,000 The transaction was accounted for as an asset acquisition pursuant to ASU 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business, as the majority of the fair value of the assets acquired was concentrated in a group of similar assets, and the acquired assets did not have outputs or employees. The assets acquired under the Exchange Agreement include exclusive worldwide sub-license to the Lymphocyte Proliferation test (LymPro Test™) for Alzheimer’s disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig. In addition, ADI holds an exclusive worldwide license to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation. Additionally, ADI owns intellectual property for the diagnosis of Parkinson’s disease (NuroPro) and Breast Cancer (BC SeraPro). The $10.1 million purchase price paid to date for these assets has been expensed in the Company’s statement of operations for the period ended September 30, 2016. Theranostics Health, Inc. On May 11, 2016, the Company entered into an Asset Purchase Agreement (“THI Purchase Agreement”) with Theranostics Health, Inc. (“THI”). The Company purchased substantially all of the assets related to THI’s business and assumed certain liabilities (the “THI Acquisition”). The Company paid an aggregate consideration of 25,000,000 shares of its common stock for the THI Acquisition. Each share of Avant common stock issued in connection with the THI Acquisition shall be subject to a lock-up beginning on May 11, 2016 and ending on the earlier of (i) eighteen (18) months after such date or (ii) a Change in Control (as defined in the Exchange Agreement) or (iii) written consent of the Company, at the Company’s sole discretion. A summary of consideration is as follows: 25,000,000 shares of the Company’s common stock $ 3,150,000 The following summarizes the current estimates of fair value of assets acquired and liabilities assumed: Amount Assets acquired: Cash $ 37,519 Accounts receivable 105,634 Intellectual property 4,120,687 Liabilities assumed: Accounts payable and accrued expenses (705,498 ) Derivative liability (8,342 ) Note payable, related party (400,000 ) Net assets acquired $ 3,150,000 The assets of the acquired consist primarily of intellectual property intangible assets. An analysis by the Company determined that substantially all the fair value of the assets on the date of acquisition is captured in the intellectual property intangible assets, as the cash and accounts receivable account for a relatively immaterial portion of the fair market value of the total assets received. The THI Acquisition was accounted for as an asset purchase in accordance with ASU 2017-01.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company’s significant estimates include the valuation of derivative liabilities, useful lives of long-lived assets, the valuation of debt and equity instruments, the valuation allowance relating to stock based compensation and the Company’s deferred tax assets. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition For revenue from product sales and services, the Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product or services has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required. The Company derives its revenue from the performance under research and development contracts. These contracts require the Company to provide services directed towards specific objectives and include developmental milestones and deliverables. Up-front payments are recorded as deferred revenue and recognized when milestones are achieved. The Company may be reimbursed for certain costs incurred in preforming the specific research and development activities and records the reimbursement as revenues. As of September 30, 2016, and 2015, deferred revenue was $-0- and $-0-.
Cost of Sales and Service	Cost of Sales and Service The cost of sales and service consists of the cost of labor, equipment depreciation, and supplies and materials.
Accounts Receivable	Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of September 30, 2016, and 2015, allowance for doubtful accounts was $-0-.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight line method over their estimated useful lives as follows: Office equipment 5 years Lab equipment 3 to 7 years
Net Loss Per Share of Common Stock	Net Loss per Share of Common Stock The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period, adjusted to give effect to the 17-for-1 reverse stock split, which was effective in the market in March 2015 (see Note 1), and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share for the years ended September 30, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: September 30, September 30, 2016 2015 Shares issued upon conversion of convertible notes and accrued interest $ 1,776,549 $ -
Intangible Assets	Intangible Assets The Company’s intangible assets consists of the following: Intellectual property for the technology transfer agreement and licensing payments for use of various patent for its worldwide exclusive licensed rights to OvaDx®, a diagnostic screening test for the early detection of ovarian cancer. As of September 30, 2016, the Company has not yet received FDA approval with respect to the clinical use of these intangible assets. The carrying value of September 30, 2016 and 2015 was $1,483,000 and $1,652,000 respectively. Intellectual property acquired from the THI Acquisition leading to the development of proteomic technologies for measuring the activation status of key signaling pathways that are instrumental in the development of companion diagnostics for molecular-targeted therapies. The Company uses these proteomic technologies to support the drug development programs of most major pharmaceutical and biotechnology drug development companies. The carrying value of September 30, 2016 and 2015 was $4,014,000 and -0-, respectively. Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Company’s intangible asset with a finite life included intellectual property acquired from THI Acquisition, capitalized website development costs and patent costs, which are being amortized over their economic or legal life, whichever is shorter. The gross carrying amounts and accumulated amortization related to acquired intangible assets as of September 30, 2016 are as follows (in thousands, except year amounts): Description Book Value as of Remaining Life (in years) Additions during Amortization Expense for the Year Ended September 30, 2016 Book Value as of License Rights to OvaDx $ 1,652 9 $ 17 $ 185 $ 1,484 THI Acquisition on May 11, 2016 - 15 $ 4,121 107 4,014 Website development cost - 5 21 16 5 Patent costs 143 9 32 111 $ 1,795 $ 4,159 $ 340 $ 5,614 The Company incurred amortization expense associated with its finite-lived intangible assets of approximately $340,000 for the year ended September 30, 2016.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets T he Company reviews the carrying value of intangibles and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair market value. During the year ended September 30, 2016 and 2015, the Company management performed an evaluation of its acquired intangible assets as of September 30, 2016 and 2015 and no impairment was deemed to exist as of September 30, 2016 and 2015. Considerable management judgment is necessary to estimate the fair value. Accordingly, actual results could vary significantly from management's estimates.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the condensed consolidated statements of operations and comprehensive loss, as if such amounts were paid in cash. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in ASU 2016-09 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact that ASU 2016-09 will have on its consolidated financial statements and related disclosures. In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the consolidated financial statements and disclosures, but does not expect it to have a significant impact.
Convertible Instruments	Convertible Instruments U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable ASC 480-10. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.
Derivative Financial Instruments	Derivative Financial Instruments The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company’s own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants, if any, and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company’s free standing derivatives consist of embedded conversion options with issued convertible notes. The Company evaluated these derivatives to assess their proper classification in the condensed consolidated balance sheets as of September 30, 2016 using the applicable classification criteria enumerated under ASC 815-Derivatives and Hedging. The Company determined that certain embedded conversion features do not contain fixed settlement provisions. The convertible notes contain a conversion feature such that the Company could not ensure it would have adequate authorized shares to meet all possible conversion demands. As such, the Company was required to record the debt derivatives which do not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period.
Segment Reporting	Segment Reporting The FASB accounting guidance regarding disclosures about segments of an enterprise and related information establishes standards for the manner in which public business enterprises report information about operating segments. The Company is managed as a single operating segment for internal reporting and for internal decision making purposes. Therefore, we have concluded that we operate as a single segment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Cash Flows In August 2016, the FASB issued ASU No. 2016-15 Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments, which addresses specific cash flow classification issues where there is currently diversity in practice including debt prepayment and proceeds from the settlement of insurance claims. ASU 2016-15 is effective for annual periods beginning after December 15, 2017, with early adoption permitted. The Company elected to early adopt ASU 2016-15 effective as of September 30, 2016. The adoption of ASU 2016-15 did not impact our results of operations or cash flows. In November 2016, the FASB issued ASU No. 2016-18 Statement of Cash Flows - Restricted Cash, which requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 is effective for annual periods beginning after December 15, 2017, with early adoption permitted. The Company elected to early adopt ASU 2016-18 including retrospective adoption for all prior periods. The impact of the adoption of ASU 2016-18 is the addition of a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet and was not material to the results. Cash The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of September 30, 2016 and 2015, the Company does not have any cash equivalents. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses are carried at amortized cost and represent liabilities for goods and services provided to the Company prior to the end of the financial year that are unpaid and arise when the Company becomes obliged to make future payments in respect of the purchase of these goods and services. Concentrations of Credit Risk The Company maintains deposits in a financial institution which is insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in this financial institution in excess of the amount insured by the FDIC. Research and Development The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic (“ASC”) 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. For the years ended September 30, 2016 and 2015, the Company’s expenditures on research and product development were $0 and $25,000 respectively. Comprehensive Income (Loss) The Company adopted ASC subtopic 220-10, Comprehensive Income (“ASC 220-10”) which establishes standards for the reporting and displaying of comprehensive income and its components. Comprehensive income is defined as the change in equity of a business during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. ASC 220-10 requires other comprehensive income (loss) to include unrealized gains and losses on available for sale securities adjustments. Income Taxes In March 2018, the FASB issued ASU 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118. ASC Topic 740 provides accounting and disclosure guidance on accounting for income taxes under generally accepted accounting principles (“U.S. GAAP”). This guidance addresses the recognition of taxes payable or refundable for the current year and the recognition of deferred tax liabilities and deferred tax assets for the future tax consequences of events that have been recognized in an entity’s financial statements or tax returns. FN1 ASC Topic 740 also addresses the accounting for income taxes upon a change in tax laws or tax rates. FN2 The income tax accounting effect of a change in tax laws or tax rates includes, for example, adjusting (or re-measuring) deferred tax liabilities and deferred tax assets, as well as evaluating whether a valuation allowance is needed for deferred tax assets. FN3 The guidance in ASC Topic 740 does not, however, address certain circumstances that may arise for registrants in accounting for the income tax effects of the Act. The staff understands from outreach that registrants will potentially encounter a situation in which the accounting for certain income tax effects of the Act will be incomplete by the time financial statements are issued for the reporting period that includes the enactment date of December 22, 2017. Questions have arisen regarding different approaches to the application of the accounting and disclosure guidance in ASC Topic 740 to such a situation. Accordingly, the SEC staff believes clarification is appropriate to address any uncertainty or diversity of views in practice regarding the application of ASC Topic 740 in situations where a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting under ASC Topic 740 for certain income tax effects of the Act for the reporting period in which the Act was enacted. The Tax Cuts and Jobs Act (the “Act”) changes existing United States tax law and includes numerous provisions that will affect businesses. The Act, for instance, introduces changes that impact U.S. corporate tax rates, business-related exclusions, and deductions and credits. The Act will also have international tax consequences for many companies that operate internationally. The Act has widespread applicability to registrants. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company adopted the provisions of ASC Topic 740-10, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of September 30, 2016 and 2015. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company classifies interest expense and any related penalties related to income tax uncertainties as a component of income tax expense. The Company did not record any income taxes during September 30, 2016. Advertising The Company’s advertising costs are expensed as incurred. Advertising expense was $0 and $600 for the years ended September 30, 2016 and 2015.
Leases	Leases In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842) Leases (Topic 840)
Business Combinations	Business Combinations In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805) Clarifying the Definition of a Business” The amendments in this ASU clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted, including for interim or annual periods for which the financial statements have not been issued or made available for issuance. The Company adopted this guidance as of September 30, 2016. See Note 3 - Acquisitions In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact of adopting this standard on the consolidated financial statements and disclosures.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.

Significant Accounting Polici20

Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2016
Defined Benefit Plan Disclosure [Line Items]
Schedule of fair value of assets acquired and liabilities assumed	Amount Assets acquired: Cash $ 37,519 Accounts receivable 105,634 Intellectual property 4,120,687 Liabilities assumed: Accounts payable and accrued expenses (705,498 ) Derivative liability (8,342 ) Note payable, related party (400,000 ) Net assets acquired $ 3,150,000
Schedule of property and equipment estimated useful lives	Office equipment 5 years Lab equipment 3 to 7 years
Schedule of weighted average dilutive common shares	September 30, September 30, 2016 2015 Shares issued upon conversion of convertible notes and accrued interest $ 1,776,549 $ -
Schedule of accumulated amortization related to acquired intangible assets	Description Book Value as of Remaining Life (in years) Additions during Amortization Expense for the Year Ended September 30, 2016 Book Value as of License Rights to OvaDx $ 1,652 9 $ 17 $ 185 $ 1,484 THI Acquisition on May 11, 2016 - 15 $ 4,121 107 4,014 Website development cost - 5 21 16 5 Patent costs 143 9 32 111 $ 1,795 $ 4,159 $ 340 $ 5,614
Amarantus Diagnostics, Inc. [Member]
Defined Benefit Plan Disclosure [Line Items]
Schedule of acquisitions consideration	80,000,000 shares of the Company’s common stock $ 10,080,000 Total purchase price 10,080,000
Theranostics Health, Inc. [Member]
Defined Benefit Plan Disclosure [Line Items]
Schedule of acquisitions consideration	25,000,000 shares of the Company’s common stock $ 3,150,000

Fair Value of Financial Instr21

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Sep. 30, 2016
Fair Value of Financial Instruments [Abstract]
Schedule of fair value conversion option was calculated using binomial lattice formula	At Inception September 30, 2016 Common Stock Estimated Fair Value $ 0.05 $ 0.05 to 0.15 Conversion Price per share 0.05-0.10 0.05-0.10 Conversion Shares 3,125,000 2,645,000 Call Option Value 0.0104 to 0.0226 0.006 to 0.11 Dividend Yield 0.00 % 0.00 % Volatility 120.00 % 120. to 133.7 % Risk-free Interest rate 0.68 % 0.26 to 0.36 % Contractual Term 0.75 to 1.00 years 0.27 to 0.69 years
Schedule of changes in fair value of Level 3 financial liabilities measured at fair value on recurring basis	Balance - Beginning of period $ - Aggregate fair value of derivative instruments issued 142,604 Transfers out upon payoff of notes payable (52,389 ) Change in fair value of derivative liabilities 33,023 Balance - End of period $ 123,238

Investment in Equity Securiti22

Investment in Equity Securities (Tables)	12 Months Ended
	Sep. 30, 2016
Investment in Equity Securities [Abstract]
Schedule of other than temporary decline in available-for-sale securities	Total loss from other-than-temporary impairment $ 2,000,000 Portion of loss previously recognized in other comprehensive income (400,000 ) Net impairment losses in the year ended September 30, 2015 $ 1,600,000

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Sep. 30, 2016
Stockholders' Equity [Abstract]
Schedule of fair value warrants	Stock price $ 0.128 Term (years) 2.5 Volatility 145 % Risk-free interest rate 1.62 % Exercise price $ 0.0001 Dividend yield 0.00 %
Schedule of common stock warrants outstanding	Number of Warrants Weighted Average Exercise Price Weighted Average Term (Years) Aggregate Intrinsic Value Warrants outstanding at September 30, 2014 2,000,000 $ 0.0001 4.9 $ - Granted 5,000,000 0.0001 5.0 - Exercised (7,000,000 ) 0.0001 4.9 - Forfeited - - - - Warrants outstanding and exercisable at September 30, 2015 - $ - - $ - Granted - - - - Exercised - - - - Forfeited - - - - Warrants outstanding and exercisable at September 30, 2016 - $ - - $ -
Schedule of stock option activity	Number of Options Weighted Average Exercise Price Weighted Average Term (Years) Aggregate Intrinsic Value Options outstanding at September 30, 2014 10,000,000 0.02 6.2 - Granted - - - - Exercised (9,882,352 ) (0.02 ) 5.8 - Forfeited (117,648 ) (0.05 ) 2.7 - Options outstanding and exercisable at September 30, 2015 - $ - - $ - Granted - - - - Exercised - - - - Forfeited - - - - Options outstanding and exercisable at September 30, 2016 - $ - - $ -

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Schedule of selling, general and administrative expenses	For the year ended Auto Allowances $ 18,000 Salaries and wages 240,000 Insurance Expense 36,000 Payroll Expenses 16,190 Travel Expenses 21,484 Total $ 331,674

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2016
Income Taxes [Abstract]
Schedule of deferred tax assets	For The Years Ended 2016 2015 Deferred Tax Assets: Net operating loss carryforward $ 5,412,924 $ 799,560 Stock-based compensation 497,325 - Marketable Securities - 788,000 Total deferred tax assets 5,910,249 1,587,560 Valuation allowance (5,910,249 ) (1,587,560 ) Deferred tax asset, net of valuation allowance $ - $ - Changes in valuation allowance $ (4,322,689 ) $ (17,440 )
Schedule of income tax provision (benefit)	For The Years Ended 2016 2015 Federal: Current $ - $ - Deferred 3,730,054 15,049 State and local: Current - - Deferred 592,632 2,391 4,322,689 (17,440 ) Change in valuation allowance (4,322,689 ) (17,440 ) Income tax provision (benefit) $ - $ -
Schedule of statutory federal income tax rate	For The Years Ended 2016 2015 Tax benefit at federal statutory rate (34.0 )% (34.0 )% State tax, net of federal benefit - % (1.04 )% Permanent differences - % 0.02 % True up of deferred tax asset - % 34.49 % Change in valuation allowance 34.0 % 0.53 % Effective income tax rate 0 % 0 %

Nature of Operations and Basi26

Nature of Operations and Basis of Presentation (Details) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 29, 2014	Sep. 30, 2016	Sep. 30, 2015	Jan. 27, 2015
Nature of Operations and Basis of Presentation (Textual)
Equity interest of ALP, percentage	100.00%
Reverse stock split, description		The 17-for-1 reverse stock split.
Recapitalization shares of common stock			3,557,777
Share price of common stock				$ 0.00001
President and CEO [Member]
Nature of Operations and Basis of Presentation (Textual)
Warrants granted		5,000,000
Fair value of warrants		$ 641,126
ALP [Member]
Nature of Operations and Basis of Presentation (Textual)
Equity interest of ALP, percentage	93.00%
Business acquisition shares of common stock	74,500,000
Reverse stock split, description	Such share exchange was calculated based on a one-for-one conversion ratio after a 1 for 17 reverse stock split of ALP which was subsequently effected in March 2015.
ALP assets	$ 0
ALP liabilities	$ 70,000

Going Concern and Management'27

Going Concern and Management's Liquidity Plans (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Going Concern and Management's Liquidity Plans (Textual)
Accumulated deficit	$ (21,573,123)	$ (9,814,078)
Net losses	(11,759,045)	(3,343,078)
Net cash used in operating activities	$ (683,004)	$ (201,612)

Significant Accounting Polici28

Significant Accounting Policies (Details)	12 Months Ended
	Sep. 30, 2016USD ($)
Significant Accounting Policies [Abstract]
80,000,000 shares of the Company's common stock	$ 10,080,000
Total purchase price	$ 10,080,000

Significant Accounting Polici29

Significant Accounting Policies (Parenthetical) (Details)	May 11, 2016shares
Amarantus Diagnostics, Inc. [Member]
Defined Benefit Plan Disclosure [Line Items]
Common stock issued to acquire, shares	80,000,000

Significant Accounting Polici30

Significant Accounting Policies (Details 1)	Sep. 30, 2016USD ($)
Significant Accounting Policies [Abstract]
25,000,000 shares of the Company's common stock	$ 3,150,000

Significant Accounting Polici31

Significant Accounting Policies (Parenthetical) (Details 1)	May 11, 2016shares
Theranostics Health, Inc. [Member]
Defined Benefit Plan Disclosure [Line Items]
Common stock issued to acquire, shares	25,000,000

Significant Accounting Polici32

Significant Accounting Policies (Details 2)	Sep. 30, 2016USD ($)
Assets acquired:
Cash	$ 37,519
Accounts receivable	105,634
Intellectual property	4,120,687
Liabilities assumed:
Accounts payable and accrued expenses	(705,498)
Derivative liability	(8,342)
Note payable, related party	(400,000)
Net assets acquired	$ 3,150,000

Significant Accounting Polici33

Significant Accounting Policies (Details 3)	12 Months Ended
	Sep. 30, 2016
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment of estimated useful lives	5 years
Lab equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment of estimated useful lives	7 years
Lab equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment of estimated useful lives	3 years

Significant Accounting Polici34

Significant Accounting Policies (Details 4) - shares	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Significant Accounting Policies [Abstract]
Shares issued upon conversion of convertible notes and accrued interest	1,776,549

Significant Accounting Polici35

Significant Accounting Policies (Details 5) $ in Thousands	12 Months Ended
	Sep. 30, 2016USD ($)
Finite-Lived Intangible Assets [Line Items]
Book Value, Gross	$ 1,795
Additions during the year	4,159
Amortization Expense	340
Book Value, Net	5,614
THI Acquisition on May 11, 2016 [Member]
Finite-Lived Intangible Assets [Line Items]
Book Value, Gross
Remaining Life	15 years
Additions during the year	$ 4,121
Amortization Expense	107
Book Value, Net	4,014
License Rights to OvaDx [Member]
Finite-Lived Intangible Assets [Line Items]
Book Value, Gross	$ 1,652
Remaining Life	9 years
Additions during the year	$ 17
Amortization Expense	185
Book Value, Net	1,484
Website development cost [Member]
Finite-Lived Intangible Assets [Line Items]
Book Value, Gross
Remaining Life	5 years
Additions during the year	$ 21
Amortization Expense	16
Book Value, Net	5
Patent costs [Member]
Finite-Lived Intangible Assets [Line Items]
Book Value, Gross	$ 143
Remaining Life	9 years
Additions during the year
Amortization Expense	32
Book Value, Net	$ 111

Significant Accounting Polici36

Significant Accounting Policies (Details Textual) - USD ($)	May 11, 2016	Sep. 30, 2016	Sep. 30, 2015	May 12, 2016	Dec. 29, 2014
Significant Accounting Policies (Textual)
Percentage of outstanding capital stock					100.00%
Purchase price		$ 10,100,000
Deferred revenue		0	$ 0
Allowance for doubtful accounts		0	0
Intangible assets carrying value		1,483,000	1,652,000
Amortization Expense		$ 340,000
Reverse stock split, description		The 17-for-1 reverse stock split.
Advertising expense		$ 0	600
Amarantus Diagnostics, Inc. [Member]
Significant Accounting Policies (Textual)
Percentage of outstanding capital stock	100.00%
Convertible promissory note	$ 50,000
Bears interest	12.00%
Initial conversion price	$ 0.20
Common stock issued to acquire, shares	80,000,000
Promissory note				$ 100,000
Theranostics Health, Inc. [Member]
Significant Accounting Policies (Textual)
Common stock issued to acquire, shares	25,000,000
Intangible assets carrying value		$ 4,014,000	$ 0

Fair Value of Financial Instr37

Fair Value of Financial Instruments (Details)	12 Months Ended
	Sep. 30, 2016$ / sharesshares
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Conversion Shares | shares	2,645,000
Dividend Yield	0.00%
Minimum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Common Stock Estimated Fair Value	$ 0.05
Conversion Price per Share	0.05
Call Option Value	$ 0.006
Volatility	120.00%
Risk-free Interest rate	0.26%
Contractual Term	3 months 8 days
Maximum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Common Stock Estimated Fair Value	$ 0.15
Conversion Price per Share	0.10
Call Option Value	$ 0.11
Volatility	133.70%
Risk-free Interest rate	0.36%
Contractual Term	8 months 9 days
At Inception [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Common Stock Estimated Fair Value	$ 0.05
Conversion Shares | shares	3,125,000
Dividend Yield	0.00%
Volatility	120.00%
Risk-free Interest rate	0.68%
At Inception [Member] | Minimum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Conversion Price per Share	$ 0.05
Call Option Value	$ 0.0104
Contractual Term	9 months
At Inception [Member] | Maximum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Conversion Price per Share	$ 0.10
Call Option Value	$ 0.0226
Contractual Term	1 year

Fair Value of Financial Instr38

Fair Value of Financial Instruments (Details 1)	12 Months Ended
	Sep. 30, 2016USD ($)
Fair Value of Financial Instruments [Abstract]
Balance - Beginning of period
Aggregate fair value of derivative instruments issued	142,604
Transfers out upon payoff of notes payable	(52,389)
Change in fair value of derivative liabilities	33,023
Balance - End of period	$ 123,238

Fair Value of Financial Instr39

Fair Value of Financial Instruments (Details Textual)	12 Months Ended
	Sep. 30, 2016
Fair Value of Financial Instruments (Textual)
Estimated conversion price, description	The Company utilized an estimated conversion price of $0.05 (or $0.10 floor as is the case with one note) in estimating the fair value of the conversion option.
Dividend yield	0.00%

Investment in Equity Securiti40

Investment in Equity Securities (Details)	12 Months Ended
	Sep. 30, 2015USD ($)
Investment in Equity Securities [Abstract]
Total loss from other-than-temporary impairment	$ 2,000,000
Portion of loss previously recognized in other comprehensive income	(400,000)
Net impairment losses in the year ended September 30, 2015	$ 1,600,000

Investment in Equity Securiti41

Investment in Equity Securities (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Aug. 31, 2014	Sep. 30, 2016	Sep. 30, 2015
Investment In Equity Securities (Textual)
Realized loss amount			$ 2,000,000
Arrayit [Member]
Investment In Equity Securities (Textual)
Available-for-sale securities, shares		10,000,000
Exchange for issuance of common shares	10,000,000

License and Technology Agreem42

License and Technology Agreements (Details) - USD ($)	Dec. 07, 2009	Sep. 10, 2009	Jul. 18, 2009	Sep. 30, 2015	Mar. 01, 2014
License and Technology Agreements (Textual)
Intellectual property, percentage			80.00%
Issuance of common stock			19,350,000
WSU [Member]
License and Technology Agreements (Textual)
License agreement, description	Under the terms of the License Agreement, the Company is obligated to make a one-time payment of $125,000 to WSU within 30 days after the approval of the first licensed product by the FDA or another comparable agency, and is obligated to make royalty payments of up to 5% of the net revenues of the licensed products on a quarterly basis, or minimum royalty payments as set forth below under the First Amendment.	The term of the Services Agreement was for five (5) years, with election to extend by the Company for an additional five (5) year period. Thereafter, the Services Agreement shall renew automatically for successive two-year periods, unless either Arrayit or the Company notifies the other of its election not to renew at least twelve (12) months prior to the expiration of the term. The term has been extended through September 2019.		The carrying value of the rights to OvaDx and payments to WSU under the License Agreement was $1,651,875, consisting of enhancements to the original initial rights licensed assigned to the Company resulting from the Tech Transfer Agreement with Arrayit as well as licensing payments made to WSU. The Company paid for these enhancements by the issuance of 10,000,000 common shares to Arrayit in August 2014, as well as cash payments to WSU. In 2015, the Company paid its clinical research organization $102,000 in conjunction with the commencement of the OvaDx to FDA trials.
Accrued patent expenses					$ 118,586
Minimum royalty of 2011					50,000
Minimum royalty of 2012					50,000
Minimum royalty of 2013					50,000
Minimum annual royalties 2014					25,000
Minimum annual royalties 2015					25,000
Minimum annual royalties 2016					50,000
Minimum annual royalties 2017					50,000
Minimum annual royalties 2018					150,000
Minimum annual royalties 2019					150,000
Minimum annual royalties 2020					$ 300,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)	Mar. 08, 2016	Sep. 30, 2016	Sep. 30, 2015	May 12, 2016	Jan. 05, 2016
Convertible Notes Payable (Textual)
Total net proceeds		$ 250,807
Interest expense		6,910
Convertible notes payable, net of unamortized discount		70,720
Debt discount		18,865
January 2016 Convertible Note [Member]
Convertible Notes Payable (Textual)
Principal amount					$ 112,500
Interest rate					10.00%
Total net proceeds		100,000
Original interest discount		$ 12,500
Conversion price		$ 0.35
Market capitalization		$ 10,000,000
Accrued interest		$ 28,750
Prepaid common stock, Description		The Note is prepaid in shares of common stock, such shares shall be issued at a 40% discount of the lowest closing bid price for the 20 consecutive trading days immediately preceding the applicable redemption date, subject to a floor of $0.10 (the "Market Price").
Fair value embedded derivatives		$ 11,669
February 2016 Amarantus Note, (Related Party) [Member]
Convertible Notes Payable (Textual)
Conversion price		$ 40.64
Fair value embedded derivatives		$ 87,037
Interest expense		18,220
Debt discount		$ 47,452
March 2016 Amarantus Note (Related Party) [Member]
Convertible Notes Payable (Textual)
Principal amount	$ 100,000
Interest rate		12.00%
Conversion price		$ 0.20
Fair value embedded derivatives	45,280	$ 19,290
Fair value embedded derivatives liability		36,201
Convertible promissory note aggregate purchase price	$ 100,000
Convertible notes payable, net of unamortized discount		23,268
Debt discount		$ 22,012	$ 0
Maximum [Member]
Convertible Notes Payable (Textual)
Conversion price		$ 0.10
Maximum [Member] | February 2016 Amarantus Note, (Related Party) [Member]
Convertible Notes Payable (Textual)
Conversion price		0.05
Maximum [Member] | March 2016 Amarantus Note (Related Party) [Member]
Convertible Notes Payable (Textual)
Conversion price	$ 0.10
Minimum [Member]
Convertible Notes Payable (Textual)
Conversion price		0.05
Minimum [Member] | February 2016 Amarantus Note, (Related Party) [Member]
Convertible Notes Payable (Textual)
Conversion price		$ 0.10
Minimum [Member] | March 2016 Amarantus Note (Related Party) [Member]
Convertible Notes Payable (Textual)
Conversion price	$ 0.05
Shareholder [Member]
Convertible Notes Payable (Textual)
Due to related party liabilities and expenses transaction				$ 100,000
Shareholder [Member] | February 2016 Amarantus Note, (Related Party) [Member]
Convertible Notes Payable (Textual)
Principal amount		$ 400,000
Previously issued convertible note		8.00%
Debt Instrument due date		Feb. 28, 2017

Stockholders' Equity (Details)

Stockholders' Equity (Details)	12 Months Ended
	Sep. 30, 2016$ / shares
Subsidiary or Equity Method Investee [Line Items]
Dividend yield	0.00%
Warrants [Member]
Subsidiary or Equity Method Investee [Line Items]
Stock price	$ 0.128
Term (years)	2 years 6 months
Volatility	145.00%
Risk-free interest rate	1.62%
Exercise price	$ 0.0001
Dividend yield	0.00%

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1) - Warrant [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Subsidiary or Equity Method Investee [Line Items]
Number of Warrants/ Options outstanding, Beginning		2,000,000
Number of Warrants/ Options, Granted		5,000,000
Number of Warrants/ Options Exercised		(7,000,000)
Number of Warrants/ Options Forfeited
Warrants outstanding/ Options outstanding, Ending
Number of Warrants/ Options, exercisable
Weighted Average Exercise Price, Warrants/ Options outstanding Beginning		$ 0.0001
Weighted Average Exercise Price, Granted		0.0001
Weighted Average Exercise Price, Exercised		0.0001
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price Warrants/ Options outstanding, Ending
Weighted Average Term (Years)	0 years	4 years 10 months 25 days
Weighted Average Term (Years), Granted	0 years	5 years
Weighted Average Term (Years), Forfeited	0 years	4 years 10 months 25 days
Weighted Average Term (Years), Exercised	0 years	0 years
Aggregate Intrinsic Value, Warrants/ Options outstanding, Beginning		$ 0
Aggregate Intrinsic Value, Granted
Aggregate Intrinsic Value, Exercised
Aggregate Intrinsic Value, Forfeited
Aggregate Intrinsic Value, Warrants/ Options outstanding, Ending

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) - Stock option [Member] - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Option Indexed to Issuer's Equity [Line Items]
Number of Warrants/ Options outstanding, Beginning		10,000,000
Number of Warrants/ Options, Granted
Number of Warrants/ Options Exercised		(9,882,352)
Number of Warrants/ Options Forfeited		(117,648)
Warrants outstanding/ Options outstanding, Ending
Number of Warrants/ Options, exercisable
Weighted Average Exercise Price, Warrants/ Options outstanding Beginning		$ 0.02
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised		(0.02)
Weighted Average Exercise Price, Forfeited		(0.05)
Weighted Average Exercise Price Warrants/ Options outstanding, Ending
Weighted Average Term (Years)	0 years	6 years 7 days
Weighted Average Term (Years), Granted	0 years	0 years
Weighted Average Term (Years), Forfeited	0 years	5 years 9 months 18 days
Weighted Average Term (Years), Exercised	0 years	2 years 26 days
Aggregate Intrinsic Value, Warrants/ Options outstanding, Beginning
Aggregate Intrinsic Value, Granted
Aggregate Intrinsic Value, Exercised
Aggregate Intrinsic Value, Forfeited
Aggregate Intrinsic Value, Warrants/ Options outstanding, Ending

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	May 11, 2016	May 05, 2016	Mar. 24, 2016	Aug. 24, 2016	Sep. 15, 2015	Apr. 22, 2015	Jan. 27, 2015	Dec. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Stockholders' Equity (Textual)
Preferred stock, shares authorized									50,000,000	50,000,000
Reverse stock split, description									The 17-for-1 reverse stock split.
Common stock, value issued									$ 2,193	$ 959
Common stock issued expenses relating to services									25,022	115,070
Legal services [Member]
Stockholders' Equity (Textual)
Common stock issued expenses relating to services										4,500
Common Stock [Member]
Stockholders' Equity (Textual)
Restricted common stock issued, shares				2,000,000
Reverse stock split, description							The Company filed an amendment to its Articles of Incorporation and effected a 17-for-1 reverse stock split of its issued and outstanding shares of common stock, whereby 109,939,000 outstanding shares of the Company’s common stock were converted into 6,467,000 shares of the Company’s common stock.
Aggregate of common stock for consulting services											$ 302,000
Aggregate of common stock for consulting services, shares											6,050,000
Common stock issued expenses relating to services									$ 32	16
Common Stock [Member] | Theranostics Health, Inc. [Member]
Stockholders' Equity (Textual)
Restricted common stock issued, shares	25,000,000
Restricted common stock issued, values	$ 3,150,000
Common Stock [Member] | Amarantus Diagnostics, Inc. [Member]
Stockholders' Equity (Textual)
Restricted common stock issued, shares	80,000,000
Restricted common stock issued, values	$ 10,080,000
Common Stock [Member] | Arrayit Corporation [Member]
Stockholders' Equity (Textual)
Common stock, shares issued											10,000,000
Common stock, value issued											$ 2,000,000
Common stock, shares issued exchange											10,000,000
Common Stock [Member] | Intellectual property [Member]
Stockholders' Equity (Textual)
Common stock, shares issued											10,000,000
Common stock, value issued											$ 1,550,000
Common Stock [Member] | Board of Directors [Member]
Stockholders' Equity (Textual)
Restricted common stock issued, shares			200,000			100,000
Restricted common stock issued, values			$ 10,000
Common stock issued expenses relating to services										7,500
Common Stock [Member] | Director [Member]
Stockholders' Equity (Textual)
Restricted common stock issued, shares		200,000
Restricted common stock issued, values		$ 10,000
Common Stock [Member] | Officer [Member]
Stockholders' Equity (Textual)
Restricted common stock issued, shares			8,569,800
Restricted common stock issued, values			$ 428,575
Common Stock [Member] | Investors [Member]
Stockholders' Equity (Textual)
Restricted common stock issued, shares					1,200,000				6,200,000		800,000
Restricted common stock issued, values					$ 180,000				$ 310,000		$ 90,000
Common stock, shares issued								2,781,666
Common stock, value issued								$ 340,000
Common stock aggregate, shares								15,000
Common stock issued expenses relating to services										90,000
Common Stock [Member] | Consulting services [Member]
Stockholders' Equity (Textual)
Restricted common stock issued, shares						87,500			745,000
Restricted common stock issued, values									$ 49,750
Aggregate vest of shares									600,000
Common stock issued expenses relating to services										7,125
Common Stock [Member] | Legal services [Member]
Stockholders' Equity (Textual)
Restricted common stock issued, shares					60,000	18,000			45,000
Restricted common stock issued, values					$ 9,000				$ 9,000
Common stock issued expenses relating to services										$ 2,700
Common Stock [Member] | Social media and investor [Member]
Stockholders' Equity (Textual)
Restricted common stock issued, shares					250,000
Restricted common stock issued, values					$ 37,500

Stockholders' Equity (Details48

Stockholders' Equity (Details Textual 1) - USD ($)	Mar. 10, 2015	Mar. 31, 2015	Sep. 30, 2016	Sep. 30, 2015
Stockholders' Equity (Textual)
Warrants exercised for cash proceeds				$ 1,300
Weighted average annual rate			0.00%	0.00%
Warrant [Member]
Stockholders' Equity (Textual)
Granted warrant				5,000,000
Warrants exercised for cash proceeds		$ 500
Fair value of warrants cost of the merger		$ 641,126
Fair value of warrants issuance date per share		$ 0.128
Options exercised				7,000,000
Issuers Capital Advisors, LLC [Member] | Warrant [Member]
Stockholders' Equity (Textual)
Granted warrant	5,000,000
Warrants immediate vesting, term	5 years
Exercised warrants shares		2,000,000
Warrant exercise price	$ 0.0001	$ 0.0001
Warrants exercised for cash proceeds		$ 200
Gregg Linn [Member]
Stockholders' Equity (Textual)
Options exercised		6,000,000
Total proceeds exercised of common stock		$ 600
Stock Options [Member]
Stockholders' Equity (Textual)
Granted warrant
Cashless exercise		3,882,352
Options exercised				9,882,352
Exercised price		$ 0.0001
Stock Options [Member] | Gregg Linn [Member]
Stockholders' Equity (Textual)
Options exercised		4,000,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - Gregg Linn [Member]	12 Months Ended
	Sep. 30, 2016USD ($)
Commitments and Contingencies (Textual)
Annual base salary	$ 240,000
Car allowance	$ 1,500
Description of commitments	The Company has agreed to pay to Mr. Linn the greater of 100% of all health care premiums of $3,000 per month.
Base compensation	30.00%

Related Party Transactions (Det

Related Party Transactions (Details)	12 Months Ended
	Sep. 30, 2016USD ($)
Related Party Transactions [Abstract]
Auto Allowances	$ 18,000
Salaries and wages	240,000
Insurance Expense	36,000
Payroll Expenses	16,190
Travel Expenses	21,484
Total	$ 331,674

Related Party Transactions (D51

Related Party Transactions (Details Textual) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Related Party Transactions (Textual)
Operating lease per month	$ 200
Rent expense	18,400	$ 2,400
Accrued expenses	256,480	141,717
Consulting and settlement expenses	17,500
Salary and professional fees	313,275	$ 110,536
Director [Member]
Related Party Transactions (Textual)
Salary and professional fees	12,500
Michael Linn [Member]
Related Party Transactions (Textual)
Salary and professional fees	$ 23,450

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Deferred Tax Assets:
Net operating loss carryforward	$ 5,412,924	$ 799,560
Stock-based compensation	497,325
Marketable Securities		788,000
Total deferred tax assets	5,910,249	1,587,560
Valuation allowance	(5,910,249)	(1,587,560)
Deferred tax asset, net of valuation allowance
Changes in valuation allowance	$ (4,322,689)	$ (17,440)

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Federal:
Current
Deferred	3,730,054	15,049
State and local:
Current
Deferred	592,632	2,391
Total	4,322,689	(17,440)
Changes in valuation allowance	(4,322,689)	(17,440)
Income tax provision (benefit)

Income Taxes (Details 2)

Income Taxes (Details 2)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Income Taxes [Abstract]
Tax benefit at federal statutory rate	(34.00%)	(34.00%)
State tax, net of federal benefit		(1.04%)
Permanent differences		0.02%
True up of deferred tax asset		34.49%
Change in valuation allowance	34.00%	0.53%
Effective income tax rate	0.00%	0.00%

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Income Taxes (Textual)
Federal and state net operating losses	$ 13,738,387	$ 2,029,517
Operating loss carryforwards, description	The net operating loss carry forwards, if not utilized, will expire 20 years from the filing of the Company's federal returns. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company's net operating loss carry forwards are subject to annual limitations in the event of a greater than 50% ownership change.

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)

Dec. 15, 2017

Sep. 05, 2017

Aug. 25, 2017

Aug. 08, 2017

Aug. 01, 2017

Jul. 28, 2017

Jul. 14, 2017

Jun. 19, 2017

Jun. 08, 2017

Sep. 19, 2017

Jul. 10, 2017

Jun. 30, 2017

Jun. 20, 2017

Jun. 02, 2017

Jan. 25, 2017

Jan. 03, 2017

Oct. 31, 2016

Jul. 18, 2009

Sep. 30, 2016

Sep. 30, 2015

Sep. 13, 2017

Jul. 06, 2017

Jul. 03, 2017

Nov. 28, 2016

Nov. 07, 2016

Subsequent Events (Textual)

Acquisition of outstanding common stock percentage

80.00%

Aggregate gross proceeds of sale of securities

$ 100,000

First settlement installment payment

$ 17,500

Preferred stock, par value

$ 0.001

$ 0.001

Increase salary per year

$ 320,000

Additional capital raise for aggregate gross proceeds

Aggregate amount of contingent liabilities

$ 310,000

$ 340,000

Exchanged shares of common stock

19,350,000

Minimum [Member]

Subsequent Events (Textual)

Conversion price

$ 0.05

Maximum [Member]

Subsequent Events (Textual)

Conversion price

0.10

Series B Preferred Stock [Member]

Subsequent Events (Textual)

Preferred stock, par value

$ 0.001

$ 0.001

Memory Dx, LLC [Member]

Subsequent Events (Textual)

Restricted common stock issued, shares

5,000,000

Restricted additional shares issued

5,000,000

Aggregate gross proceeds of sale of securities

$ 7,500,000

Forecast [Member]

Subsequent Events (Textual)

Principal amount

$ 51,200

$ 786,500

$ 65,000

Debt instrument, description

The Company agreed to get current in its ongoing reporting requirements with the Securities and Exchange Commission within 120 days of the execution of the October 2016 Investors Exchange Agreement. If the Company does not get current within the 120-day period, the New October 2016 Notes are null and void and shall revert back to the original notes issued to the investors. In connection with the issuance of the New October 2016 Notes, the October 2016 Investors agreed to waive all accrued interest and penalties related to the October 2016 Notes, upon getting current and releasing from escrow to issue through the execution date of the exchange for the purchase an aggregate of 793,390 shares of the Company’s common stock.

Convertible promissory note aggregate purchase price

$ 325,000

$ 605,000

$ 65,000

Notes bear interest rate

8.00%

8.00%

8.00%

8.00%

8.00%

12.00%

Maturity issuance date

Jul. 28, 2019

Jan. 15, 2018

Conversion price

$ 0.06

$ 0.06

$ 0.15

Conversion price, description

The Oct 2016 Notes will be convertible at the option of the holder at any time into shares of common stock, at an initial conversion price equal to the lesser of (i) $0.25 or (ii) the closing sales price of such common stock on the date of conversion, subject to adjustment.

Additional investment

$ 75,000

$ 75,000

$ 75,000

$ 75,000

Total investment size, fair value

$ 525,000

$ 50,000

$ 75,000

Investment additional information, description

Investor received an aggregate of 150,000 shares of common stock as commitment shares, a warrant to purchase such number of shares of common stock equal to 200% of their subscription amount divided by the June 2017 Initial Conversion Price and a purchase right to purchase such number of shares of common stock equal to 800% of their subscription amount divided by the June 2017 Initial Conversion Price. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $0.06. The purchase right is exercisable beginning on the eighteen (18) month anniversary of the date of issuance until the five-year anniversary of the date of issuance at an initial exercise price of $0.06.

Investor received an aggregate of 100,000 shares of common stock as commitment shares, a warrant to purchase such number of shares of common stock equal to 200% of their subscription amount divided by the June 2017 Initial Conversion Price and a purchase right to purchase such number of shares of common stock equal to 800% of their subscription amount divided by the June 2017 Initial Conversion Price. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $0.06. The purchase right is exercisable beginning on the eighteen (18) month anniversary of the date of issuance until the five-year anniversary of the date of issuance at an initial exercise price of $0.06.

Investor received an aggregate of 150,000 shares of common stock as commitment shares, a warrant to purchase such number of shares of common stock equal to 200% of their subscription amount divided by the June 2017 Initial Conversion Price and a purchase right to purchase such number of shares of common stock equal to 800% of their subscription amount divided by the June 2017 Initial Conversion Price. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $0.06. The Purchase right is exercisable beginning on the eighteen (18) month anniversary of the date of issuance until the five-year anniversary of the date of issuance at an initial exercise price of $0.06.

In connection with the Agreement, the June 2017 Investor received an aggregate of 650,000 shares of common stock (the "June 2017 Commitment Shares"), a warrant to purchase such number of shares of common stock equal to 200% of their subscription amount divided by the June 2017 Initial Conversion Price (the "June 2017 Warrant") and a purchase right to purchase such number of shares of common stock equal to 800% of their subscription amount divided by the June 2017 Initial Conversion Price (the "June 2017 Right"). The June 2017 Note, June 2017 Commitment Shares, June 2017 Warrant and June 2017 Purchase Right are collectively referred to herein as the "June 2017 Investment". The June 2017 Warrant is exercisable for a period of five years from the date of issuance at an initial exercise price of $0.06. The June 2017 Right is exercisable beginning on the eighteen (18) month anniversary of the date of issuance until the five-year anniversary of the date of issuance at an initial exercise price of $0.06.

Preferred stock conversion basis in the June 2017 investment, description

Investment could be exchanged and/or converted into a class of the Company's preferred stock to be created (the "Preferred Stock") that is convertible into the equivalent of 49.99% of the then outstanding common stock of the Company pro-rata on an as converted basis based upon a total investment of $750,000 into the June 2017 Investment.

Increase salary per year

$ 360,000

Additional capital raise for aggregate gross proceeds

500,000

Aggregate amount of contingent liabilities

$ 375,000

Exchanged shares of common stock

6,250,000

Forecast [Member] | Minimum [Member]

Subsequent Events (Textual)

Total investment size, fair value

$ 400,000

Forecast [Member] | Maximum [Member]

Subsequent Events (Textual)

Total investment size, fair value

$ 750,000

Forecast [Member] | Gregg Linn [Member]

Subsequent Events (Textual)

Separation and release agreement, description

Pursuant to the Agreement, the Company shall (a) pay Mr. Linn a lump sum cash payment of $30,000 upon on the Effective Date (as defined in the Agreement), (b) reimburse Mr. Linn for expenses paid on behalf of the Company, $2,500 of which will be paid on the Effective Date and $2,978.41 to be paid out of the proceeds of the first closing of the next financing of the Company's equity and/or debt securities to be consummated after the completion of the Financing and (c) upon the earliest occurrence of a Triggering Event (as defined in the Separation Agreement), the Company shall pay Mr. Linn a lump sum cash payment of $180,000 within three (3) business days of the date a Triggering Event occurs. In addition, the Company shall issue Mr. Linn 15,000,000 restricted shares of the Company's common stock ("Equity Issue") which Equity Issue shall vest quarterly over three (3) years from the termination date in accordance with the terms of that certain restricted stock award agreement.

Forecast [Member] | Dr. Goix [Member]

Subsequent Events (Textual)

Separation and release agreement, description

The Company entered into a Separation and Release Agreement (the "Goix Separation Agreement") with Philippe Goix, the Company's former Chief Executive Officer, pursuant to which Dr. Goix's status as chief executive officer and director of the Company ended effective December 4, 2017. Pursuant to the Goix Separation Agreement, upon the occurrence of a Triggering Event (as defined in the Goix Separation Agreement), the Company shall pay Dr. Goix a lump sum cash payment of $27,346.84 within three (3) business days of the date such Triggering Event occurs.

Annual base salary

120,000

Sign-on bonus

15,000

Accrued travel expenses

$ 4,500

Option to purchase common stock

22,000,000

Additional sale of equity and/or debt securities

1,750,000

Increase salary per year

$ 240,000

Additional capital raise for aggregate gross proceeds

$ 5,000,000

Forecast [Member] | Dr. Goix [Member] | Bonus [Member]

Subsequent Events (Textual)

Salary and related compensation arrangement, description

Upon the Company raising an additional $1,500,000 through the sale of its equity and/or debt securities (excluding any securities sold in the Company's financing disclosed on a Current Report on Form 8-K filed with the Commission on June 20, 2017) (the "Financing"), Dr. Goix shall be entitled to a cash bonus equal to the following: (i) $50,000 if the Financing is completed within 3 months of the date of the Offer Letter, (ii) $40,000 if the Financing is completed within 5 months of the date of the Offer Letter, and (iii) $30,000 if the Financing is completed within 7 months of the date of the Offer Letter.

Forecast [Member] | Series B Preferred Stock [Member]

Subsequent Events (Textual)

Series B preferred stock exchange for cancellation

3,000

Stock cancellation accrued but unpaid compensation

$ 98,000

Preferred stock, par value

$ 0.001

Forecast [Member] | Prism Health Dx, Inc. [Member]

Subsequent Events (Textual)

Principal amount

$ 200,000

Notes bear interest rate

5.00%

Acquisition of outstanding common stock percentage

100.00%

Shares of common stock percentage

50.00%

Proceed from extinguishment of the Bridge Note

$ 100,000

Forecast [Member] | Memory Dx, LLC [Member]

Subsequent Events (Textual)

Debt instrument, description

(i) an aggregate of $250,000 (the "Cash Consideration") payable as follows: (i) $35,000 which has been previously paid, (ii) $3,500 which was paid upon execution of the agreement (iii) $2,000 which will be payable on the last calendar day of each month for October and November 2017, (iv) $5,000 which will be payable on the last calendar day for December 2017 and each of January and February 2018 and (v) $10,000 which will be payable on the last calendar day of each month until the full consideration is paid. Notwithstanding the foregoing, upon the sale by the Company of its equity securities in a single offering for aggregate gross proceeds of at least $7,500,000 (the "Qualified Offering") after the date of the agreement, the Company will pay any remaining amount of the Cash Consideration then outstanding upon the final closing of such Qualified Offering.

Forecast [Member] | John G. Hartwell [Member]

Subsequent Events (Textual)

Amount agreed to pay Defendants

$ 154,000

First settlement installment payment

$ 29,819.99

Forecast [Member] | Black Mountain Equity Partners LLC [Member]

Subsequent Events (Textual)

Principal amount

$ 25,000

Debt instrument actual payment

$ 25,000

Restricted common stock issued, shares

62,500

Forecast [Member] | Coastal Investment Partners, LLC [Member]

Subsequent Events (Textual)

Principal amount

$ 380,250

Debt instrument, description

Pursuant to the terms of the Coastal Exchange Agreement, the Company and Coastal agreed to exchange the New Coastal51 Notes for the issuance of new convertible promissory notes due July 14, 2019 in the aggregate principal amount of $442,325.00, (the "New Coastal Note"). In connection with the Coastal Exchange Agreement, the Company and the investor agreed to a binding letter of intent whereby the Company agreed, to among other things, upon getting current and releasing the New Coastal Note from escrow to issue the investor 750,000 shares of the Company's common stock related to an adjustment that resulted under the July 2016 Notes because of the issuance of the Nov 2016 Notes and the Company agreed to get current in its ongoing reporting requirements with the Securities and Exchange Commission within 90 days of the execution of the Coastal Exchange Agreement. If the Company does not get current within the 90-day period, the New Coastal Notes are null and void and shall revert back to the Coastal51 Notes issued to the investors.

Subsequent Events (Details 1)

Subsequent Events (Details 1) - USD ($)	Dec. 15, 2017	Oct. 06, 2017	May 25, 2018	Mar. 30, 2018	Sep. 30, 2016	Sep. 30, 2015	Sep. 13, 2017
Subsequent Events (Textual)
Preferred stock, par value					$ 0.001	$ 0.001
Aggregate gross proceeds					$ 310,000	$ 340,000
Exchanged an aggregate of amount					1,776,549
Series B preferred stock
Subsequent Events (Textual)
Preferred stock, par value					$ 0.001	$ 0.001
Forecast [Member]
Subsequent Events (Textual)
Securities purchase agreement, description		The Company entered into a securities purchase agreement with the June 2017 Investor pursuant to which the June 2017 Investor purchased $20,000 of the June 2017 Investment for an aggregate purchase price of $20,000 (the "October 2017 Investment"). The June 2017 notes bear interest at 8% and mature thirty-six months from the date of issuance. The June 2017 Notes will be convertible at the option of the holder at any time into shares of common stock, at the June 2017 Initial Conversion Price. In connection with the agreement, the June 2017 Investor received an aggregate of 40,000 shares of common stock as commitment shares, a warrant to purchase such number of shares of common stock equal to 200% of their subscription amount divided by the June 2017 Initial Conversion Price and a purchase right to purchase such number of shares of common stock equal to 800% of their subscription amount divided by the June 2017 Initial Conversion Price. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $0.06. The purchase right is exercisable beginning on the eighteen (18) month anniversary of the date of issuance until the five-year anniversary of the date of issuance at an initial exercise price of $0.06.
Asset purchase agreement, description				The Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Amarantus Bioscience Holdings, Inc., a Nevada corporation ("AMBS") pursuant to which the Company sold all intellectual property related to its MSPrecise®, Lympro®, and NuroPro® assets to AMBS in exchange for, among other things, the following: (i) cancellation of all principal, interest and other amounts owed to AMBS pursuant to those certain promissory notes issued on February 28, 2016 (which was assumed by the Company in connection with that certain asset purchase agreement, dated May 11, 2016, by and between the Company and Theranostics Health, Inc.) and March 7, 2016 (of which $100,000 has been paid to date), (ii) assumption by AMBS of $322,500 of contingent liabilities assumed by the Company pursuant to the terms of that certain share exchange agreement, dated May 11, 2016, by and between the Company and AMBS (the "Exchange Agreement"), (iii) the issuance by AMBS of 1,000,000 shares of its common stock to the Company, subject to a lock-up period substantially similar to the lock-up period described below and (iv) the issuance of approximately 30,092,743 shares by the Company to AMBS in satisfaction of all remaining amounts owed to AMBS pursuant to the terms of the Exchange Agreement, subject to the lockup period described below (the "Transaction"). The Transaction closed upon the execution of the Purchase Agreement. The Company issued an aggregate consideration of 30,092,743 shares of its common stock for the Transaction (the "Consideration"). Each share of Company common stock received in connection with the Transaction shall be subject to a lock-up beginning on the Effective Date and ending on the earlier of (i) eighteen (18) months after such date or (ii) a Change in Control (as defined in the Purchase Agreement) or (iii) written consent of the Company, at the Company's sole discretion.
Sell for cash to investors pro rata basis aggregate of common stock			$ 1,000,000
Subsequent event, description			The Company's 2019 annual meeting of stockholders, the Investors, jointly and severally, shall have the exclusive right, voting separately as a class, to elect up to six (6) directors (each director, an "Investor Director"). A Preferred Director so elected shall serve for a term of one year and until his successor is elected and qualified. An Investor Director may, during his or her term of office, be removed at any time, with or without cause, by and only by the affirmative vote, at a special meeting of holders of Series A Preferred Stock called for such purpose. Any vacancy created by such removal may also be filled at such meeting or by such consent for the remainder of such initial one year term. At any time on or after the Effective Date and until the Company's 2019 annual meeting of stockholders, Infusion 51a, LP ("Infusion") shall have the right to elect up to three (3) directors (each director, an "Infusion Director").
Reverse stock split, shares			15,000,000
Percentage of discount to the average closing price of the common stock			10.00%
Investor representative annual amount			$ 160,000
Subscription amount			$ 150,000
Placement agent, description			We agreed to pay our placement agent, a registered broker-dealer, or the Placement Agent, (i) a cash commission of 8% of the gross proceeds raised from investors in the offering, and to issue to the Placement Agent warrants to purchase a number of shares of common stock equal to 4% of the gross proceeds divided by the respective offering price, with a term of seven years from the date of issuance.
Forecast [Member] | Series A preferred stock [Member]
Subsequent Events (Textual)
Exchanged an aggregate of amount			516,155
Exchanged an aggregate of shares			$ 516,155
Forecast [Member] | Series B preferred stock
Subsequent Events (Textual)
Preferred stock, par value							$ 0.001
Forecast [Member] | Series A convertible preferred stock [Member]
Subsequent Events (Textual)
Sold an aggregate of shares			(650,000)
Aggregate gross proceeds			$ 650,000
Forecast [Member] | 2017 Notes [Member]
Subsequent Events (Textual)
Investors exchange agreement, description			The Company entered into an exchange agreement (collectively, the "2017 Investors Exchange Agreement") with the investors who purchased convertible promissory notes between June 2017 and October 2017 (the "2017 Notes") for an aggregate principal amount of $545,000 (the "2017 Investors"). Pursuant to the terms of the 2017 Investors Exchange Agreement, the Company agreed to exchange (i) the principal amount due under the 2017 Notes (ii) warrants to purchase 18,166,667 shares of common stock and (iii) purchase rights to purchase shares of common stock for an aggregate of 72,666,667 shares of common stock, in exchange for an aggregate approximately 22,290,800 shares of series B convertible preferred stock having an aggregate value of $545,000 (the "Series B Preferred Stock"). The 2017 Investors have agreed to waive the defaults and breaches that have resulted on or prior to the Effective Date as well as any penalties, interest or other amounts that may have accrued under the 2017 Notes after March 31, 2018.
Forecast [Member] | 2016 Notes [Member]
Subsequent Events (Textual)
Investors exchange agreement, description			The Company entered into an exchange agreement (collectively, the "2016 Investors Exchange Agreement") with the investors who purchased convertible promissory notes between November 2016 and January 2017 (the "2016 Notes") for an aggregate principal amount of $786,500 (the "2016 Investors"). Pursuant to the terms of the 2016 Investors Exchange Agreement, the Company agreed to exchange (i) the principal amount due under the 2016 Notes in exchange for an aggregate of (i) 323,323 shares of Series A Preferred Stock having an aggregate value of $323,323 and (ii) approximately 3,324,065 shares of series B convertible preferred stock having an aggregate value of approximately $498,610 (the "Series B Preferred Stock") and (iii) exchange for the issuance of new promissory note due twenty-four (24) months from the Effective Date in the aggregate principal amount of $47,259 (the "New 2016 Investor Note"). The New 2016 Investor Note shall bear interest at 12% per annum and has mandatory payments of $2,000 every 30 days until paid in full starting June 25, 2018.
Dr. Goix [Member] | Forecast [Member]
Subsequent Events (Textual)
Separation and release agreement, description	The Company entered into a Separation and Release Agreement (the "Goix Separation Agreement") with Philippe Goix, the Company's former Chief Executive Officer, pursuant to which Dr. Goix's status as chief executive officer and director of the Company ended effective December 4, 2017. Pursuant to the Goix Separation Agreement, upon the occurrence of a Triggering Event (as defined in the Goix Separation Agreement), the Company shall pay Dr. Goix a lump sum cash payment of $27,346.84 within three (3) business days of the date such Triggering Event occurs.

Subsequent Events (Details 2)

Subsequent Events (Details 2) - Forecast [Member]	1 Months Ended
	May 25, 2018
Subsequent Events (Textual)
Coastal exchange agreement, description	The Company entered into an exchange Agreement (the "Coastal Exchange Agreement") with Coastal Investment Partners, LLC ("Coastal"). Pursuant to the terms of the Coastal Exchange Agreement, the Company agreed to exchange the principal amount due under the convertible promissory note dated July 6, 2016 plus accrued but unpaid interest and default and other amounts due and payable under such notes, which was $305,664 as of the Effective Date (the "Coastal Notes") in exchange for (i) 192,832 shares of Series A Preferred Stock having an aggregate value of $192,832 and (ii) the issuance of new convertible promissory notes due eighteen (18) months from the Effective Date in the aggregate principal amount of $192,832 (the "New Coastal Note"). The New Coastal Note shall bear interest at 8% per annum and is convertible into shares of the Company's common stock at $0.015 per share, subject to adjustment. Coastal has contractually agreed to restrict their ability to convert the New Coastal Note such that the number of shares of the Company common stock held by them and their affiliates after such conversion does not exceed 9.99% of the Company's then issued and outstanding shares of common stock. In connection with the Coastal Exchange Agreement, Coastal agreed to waive the defaults and breaches that have resulted on or prior to the Effective Date as well as any penalties, interest or other amounts that may have accrued under the Coastal Notes after March 31, 2018.
Black mountain exchange agreement, description	The Company entered into an exchange agreement (the "Black Mountain Exchange Agreement") with Black Mountain Equity Partners LLC ("Black Mountain"). Pursuant to the terms of the Black Mountain Exchange Agreement, the Company agreed to exchange the principal amount due under the convertible promissory note dated November 11, 2016 (the "Black Mountain Note") in exchange for the issuance of new promissory note due twelve (12) months from the Effective Date in the aggregate principal amount of $20,000 (which includes a prepayment amount of $5,000 made on the Effective Date) (the "New Black Mountain Note"). The New Black Mountain Note shall bear interest at 12% per annum and has mandatory payments of $5,000 every 90 days until paid in full. In connection with the Black Mountain Exchange Agreement, Black Mountain agreed to waive the defaults and breaches that have resulted on or prior to the Effective Date as well as any penalties, interest or other amounts that may have accrued under the Black Mountain Note after March 31, 2018.
Dr Ruxin [Member]
Subsequent Events (Textual)
Employment agreement, description	The Company entered into an employment agreement (the "Ruxin Agreement") with Dr. Ruxin under which he will serve as Chief Executive Officer of the Company. The term of the Ruxin Agreement was effective as of May 25, 2018, continues until May 25, 2023 and automatically renews for successive one year periods at the end of each term until either party delivers written notice of their intent not to renew at least 60 days prior to the expiration of the then effective term. Under the terms of the Ruxin Agreement, Dr. Ruxin will receive an annual salary of $250,000. He is eligible to receive a cash bonus of up to 100% of his base salary. The bonus shall be earned upon the Company's achievement of performance targets for a fiscal year to be mutually agreed upon by Dr. Ruxin and the board or a committee thereof. Additionally, following the adoption by the Company of an equity compensation plan and subject to approval of the board or a committee thereof, Dr. Ruxin shall receive (i) a one-time restricted stock unit award having a fair value of approximately $100,000 and which shall vest over a five year period following the date of grant and (ii) an option to purchase ten percent (10%) of the outstanding shares of the Company (calculated on the date of grant), which shall vest over a five-year period following the date of grant and expire on the tenth anniversary of the date of grant.
Mr Busch [Member]
Subsequent Events (Textual)
Employment agreement, description	The Company entered into an employment agreement (the "Busch Agreement") with Mr. Busch under which he will serve as Executive Chairman of the Company. The term of the Busch Agreement was effective as of May 25, 2018, continues until May 25, 2023 and automatically renews for successive one year periods at the end of each term until either party delivers written notice of their intent not to renew at least 60 days prior to the expiration of the then effective term. Under the terms of the Busch Agreement, Mr. Busch will receive an annual salary of $30,000, which amount shall be automatically increased to $120,000 on the first anniversary of the date of the Busch Agreement. He is eligible to receive a discretionary cash bonus at the option of the board based on their evaluation of his performance of duties and responsibility. Additionally, following the adoption by the Company of an equity compensation plan and subject to approval of the board or a committee thereof, Mr. Busch shall receive (i) a one-time restricted stock unit award having a fair value of approximately $100,000 and which shall vest over a five year period following the date of grant and (ii) an option to purchase ten percent (10%) of the outstanding shares of the Company (calculated on the date of grant), which shall vest over a five-year period following the date of grant and expire on the tenth anniversary of the date of grant.